Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 634 articles:
HTML format



Single Articles


    September 2020
  1. MILLER JJ, Cahill DP
    MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.
    Neuro Oncol. 2020 Sep 14. pii: 5905585. doi: 10.1093.
    PubMed    


  2. WEI Y, Lu C, Zhou P, Zhao L, et al
    EIF4A3-induced circular RNA ASAP1(circASAP1) promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1/2 signaling.
    Neuro Oncol. 2020 Sep 14. pii: 5905565. doi: 10.1093.
    PubMed     Abstract available


  3. KHUONG-QUANG DA, Hansford JR
    Preoperative chemotherapy in medulloblastoma: A change in treatment paradigm?
    Neuro Oncol. 2020 Sep 12. pii: 5904992. doi: 10.1093.
    PubMed    


  4. JOHNSON RM, Phillips HS, Bais C, Brennan CW, et al
    Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
    Neuro Oncol. 2020 Sep 8. pii: 5902781. doi: 10.1093.
    PubMed     Abstract available


  5. BALANA C, Carrato C, Vaz MA
    Reply to: 'Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?'
    Neuro Oncol. 2020 Sep 4. pii: 5901531. doi: 10.1093.
    PubMed    


  6. PARK JW, Sahm F, Steffl B, Arrillaga-Romany I, et al
    TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
    Neuro Oncol. 2020 Sep 3. pii: 5901083. doi: 10.1093.
    PubMed     Abstract available


  7. KOTECHA R, Hall MD
    Impact of Radiotherapy Dosimetric Parameters on Neurocognitive Function in Brain Tumor Patients.
    Neuro Oncol. 2020 Sep 2. pii: 5900405. doi: 10.1093.
    PubMed    


    August 2020
  8. HE Y, Li J, Koga T, Ma J, et al
    Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors.
    Neuro Oncol. 2020 Aug 24. pii: 5896390. doi: 10.1093.
    PubMed     Abstract available


  9. ECKER J, Thatikonda V, Sigismondo G, Selt F, et al
    Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
    Neuro Oncol. 2020 Aug 21. pii: 5895493. doi: 10.1093.
    PubMed     Abstract available


  10. NIE E, Jin X, Miao F, Yu T, et al
    TGF-beta1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
    Neuro Oncol. 2020 Aug 19. pii: 5894410. doi: 10.1093.
    PubMed     Abstract available


  11. ROSSMEISL JH, Herpai D, Quigley M, Cecere TE, et al
    Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas.
    Neuro Oncol. 2020 Aug 19. pii: 5894210. doi: 10.1093.
    PubMed     Abstract available


  12. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Hippocampal Avoidance Whole-brain Radiotherapy without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase II Blinded Randomized Trial.
    Neuro Oncol. 2020 Aug 13. pii: 5892223. doi: 10.1093.
    PubMed     Abstract available


  13. JOO L, Park JE, Park SY, Nam SJ, et al
    Extensive Peritumoral Edema and Brain-to-Tumor Interface MR Imaging Features Enable Prediction of Brain Invasion in Meningioma: Development and Validation.
    Neuro Oncol. 2020 Aug 13. pii: 5892102. doi: 10.1093.
    PubMed     Abstract available


  14. DANIEL AGS, Park KY, Roland JL, Dierker D, et al
    Functional connectivity within glioblastoma impacts overall survival.
    Neuro Oncol. 2020 Aug 13. pii: 5892093. doi: 10.1093.
    PubMed     Abstract available


  15. TRAN AN, Horbinski C
    Mesenchymal stem-like cells in glioblastoma.
    Neuro Oncol. 2020 Aug 12. pii: 5891766. doi: 10.1093.
    PubMed    


  16. MILANO MT, Chiang VLS, Soltys SG, Wang TJC, et al
    Executive Summary from American Radium Society's Appropriate Use Criteria on Neurocognition after stereotactic radiosurgery for multiple brain metastases.
    Neuro Oncol. 2020 Aug 11. pii: 5891284. doi: 10.1093.
    PubMed     Abstract available


  17. GUPTA T, Chatterjee A, Patil V
    Extended adjuvant temozolomide in newly-diagnosed glioblastoma: is more less?
    Neuro Oncol. 2020 Aug 10. pii: 5890517. doi: 10.1093.
    PubMed    


  18. PACKER RJ, MacDonald TJ
    Integrated Analysis of Pediatric Low-Grade Glioma (PLGGs): Clinical Implications and the Path Forward.
    Neuro Oncol. 2020 Aug 8. pii: 5885400. doi: 10.1093.
    PubMed    


  19. FULTS DW
    Marauding Monocytes, Macrophages, and Microglia in Gliomas.
    Neuro Oncol. 2020 Aug 8. pii: 5885299. doi: 10.1093.
    PubMed    


  20. HOSSAIN JA, Miletic H
    Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas".
    Neuro Oncol. 2020 Aug 8. pii: 5885399. doi: 10.1093.
    PubMed    


  21. MOHAN R, Liu AY, Brown PD, Mahajan A, et al
    Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons.
    Neuro Oncol. 2020 Aug 5. pii: 5880625. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  22. ARANA E, Arribas LA
    Letter regarding "Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases".
    Neuro Oncol. 2020 Jul 31. pii: 5879447. doi: 10.1093.
    PubMed    


  23. CHOI YS, Bae S, Chang JH, Kang SG, et al
    Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics.
    Neuro Oncol. 2020 Jul 24. pii: 5876011. doi: 10.1093.
    PubMed     Abstract available


  24. WILCOX JA, Boire AA
    Palliation for all people: alleviating racial disparities in supportive care for brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874496. doi: 10.1093.
    PubMed    


  25. LAMBA N, Catalano PJ, Haas-Kogan DA, Wen PY, et al
    Utility of claims data for delineation of intracranial treatment among patients with brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874115. doi: 10.1093.
    PubMed    


  26. WORONIECKA K, Fecci PE
    Immuno-Synergy? Neoantigen Vaccines and Checkpoint Blockade in Glioblastoma.
    Neuro Oncol. 2020 Jul 21. pii: 5874112. doi: 10.1093.
    PubMed    


  27. CHILUKURI S, Jalali R
    Reassuring quality of life in younger childhood (<4 years) brain tumor survivors treated with proton beam therapy.
    Neuro Oncol. 2020 Jul 17. pii: 5873257. doi: 10.1093.
    PubMed    


  28. SCHMAINDA KM, Prah MA, Marques H, Kim E, et al
    Value of Dynamic Contrast Perfusion MRI to Predict Early Response to Bevacizumab in Newly Diagnosed Glioblastoma: Results from ACRIN 6686 Multi-Center Trial.
    Neuro Oncol. 2020 Jul 17. pii: 5873138. doi: 10.1093.
    PubMed     Abstract available


  29. HOLLON TC, Pandian B, Urias E, Save AV, et al
    Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated Raman histology and deep neural networks.
    Neuro Oncol. 2020 Jul 16. pii: 5872473. doi: 10.1093.
    PubMed     Abstract available


  30. JIN L, Shi F, Chun Q, Chen H, et al
    Artificial Intelligence Neuropathologist for Glioma Classification using Deep Learning on Hematoxylin and Eosin Stained Slide images and Molecular Markers.
    Neuro Oncol. 2020 Jul 14. pii: 5871429. doi: 10.1093.
    PubMed     Abstract available


  31. SANTANGELO A, Rossato M, Lombardi G, Benfatto S, et al
    A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.
    Neuro Oncol. 2020 Jul 14. pii: 5871069. doi: 10.1093.
    PubMed     Abstract available


  32. ALMAHARIQ MF, Quinn TJ, Arden JD, Roskos PT, et al
    Pulsed Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2020 Jul 13. pii: 5870764. doi: 10.1093.
    PubMed     Abstract available


  33. BAKAS S, Ormond DR, Alfaro KD, Smits M, et al
    iGLASS: Imaging integration into the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2020 Jul 9. pii: 5869362. doi: 10.1093.
    PubMed    


  34. AZIZI AA, Walker DA, Liu JF, Sehested A, et al
    NF1 optic pathway glioma. Analysing risk factors for visual outcome and indications to treat.
    Neuro Oncol. 2020 Jul 6. pii: 5867970. doi: 10.1093.
    PubMed     Abstract available


  35. VENKATARAMANI V, Tanev DI, Kuner T, Wick W, et al
    Synaptic Input to Brain Tumors: Clinical Implications.
    Neuro Oncol. 2020 Jul 5. pii: 5867510. doi: 10.1093.
    PubMed     Abstract available


  36. CARAI A, Locatelli F, Mastronuzzi A
    Delayed referral of pediatric brain tumors during COVID-19 pandemic.
    Neuro Oncol. 2020 Jul 5. pii: 5867513. doi: 10.1093.
    PubMed    


  37. DUNN GP, Cloughesy TF, Maus MV, Prins RM, et al
    Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy.
    Neuro Oncol. 2020 Jul 2. pii: 5866670. doi: 10.1093.
    PubMed     Abstract available


  38. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Neuro Oncol. 2020 Jul 1. pii: 5866079. doi: 10.1093.
    PubMed    


    June 2020
  39. ZHANG A, Tao W, Zhai K, Fang X, et al
    Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy.
    Neuro Oncol. 2020 Jun 27. pii: 5864095. doi: 10.1093.
    PubMed     Abstract available


  40. TURAGA SM, Silver DJ, Bayik D, Paouri E, et al
    JAM-A functions as a female microglial tumor suppressor in glioblastoma.
    Neuro Oncol. 2020 Jun 27. pii: 5864028. doi: 10.1093.
    PubMed     Abstract available


  41. VAN TELLINGEN O, de Gooijer MC, Sarkaria JN, Elmquist WF, et al
    Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".
    Neuro Oncol. 2020 Jun 18. pii: 5859434. doi: 10.1093.
    PubMed    


  42. BOXERMAN JL, Quarles CC, Hu LS, Erickson BJ, et al
    Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.
    Neuro Oncol. 2020 Jun 9. pii: 5855183. doi: 10.1093.
    PubMed     Abstract available


  43. EATON BR, Yock TI
    Radiation for Pediatric Low Grade Gliomas: who will benefit and how late is soon enough?
    Neuro Oncol. 2020 Jun 9. pii: 5855151. doi: 10.1093.
    PubMed    


  44. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
    Neuro Oncol. 2020 Jun 9. pii: 5854970. doi: 10.1093.
    PubMed    


  45. GROSSMAN SA, Romo CG, Rudek MA, Supko J, et al
    Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
    Neuro Oncol. 2020 Jun 7. pii: 5854364. doi: 10.1093.
    PubMed    


  46. LEACH JL, Roebker J, Schafer A, Baugh J, et al
    MR Imaging features of Diffuse Intrinsic Pontine Glioma (DIPG) and Relationship to Overall Survival: Report from the International DIPG Registry.
    Neuro Oncol. 2020 Jun 6. pii: 5854320. doi: 10.1093.
    PubMed     Abstract available


  47. ZHANG LH, Yin YH, Chen HZ, Feng SY, et al
    TRIM24 Promotes Stemness and Invasiveness of Glioblastoma Cells via Activating SOX2 Expression.
    Neuro Oncol. 2020 Jun 3. pii: 5850997. doi: 10.1093.
    PubMed     Abstract available


  48. KOTECHA R, Mehta MP
    Extreme Hypofractionation for Newly Diagnosed Glioblastoma: Rationale, Dose, Techniques, and Outcomes.
    Neuro Oncol. 2020 Jun 1. pii: 5849843. doi: 10.1093.
    PubMed    


  49. MASSIMINO M, Giangaspero F
    Editorial: High-grade gliomas in adolescents and young adults reveal histomolecular differences vis-a-vis their adult and pediatric counterparts.
    Neuro Oncol. 2020 Jun 1. pii: 5849851. doi: 10.1093.
    PubMed    


  50. HAGGIAGI A, Lassman AB
    Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
    Neuro Oncol. 2020 Jun 1. pii: 5849858. doi: 10.1093.
    PubMed    


  51. SAMMONS S, Van Swearingen AED, Anders CK
    Receptor Discordance in Breast Cancer Brain Metastases: When Knowledge is Power.
    Neuro Oncol. 2020 Jun 1. pii: 5849911. doi: 10.1093.
    PubMed    


    May 2020
  52. BUCCARELLI M, Lulli V, Giuliani A, Signore M, et al
    Deregulated expression of the imprinted DLK1-DIO3 region in Glioblastoma Stem-like Cells: tumor suppressor role of lncRNA MEG3.
    Neuro Oncol. 2020 May 27. pii: 5847771. doi: 10.1093.
    PubMed     Abstract available


  53. KAUR E, Nair J, Ghorai A, Mishra SV, et al
    Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevent glioblastoma recurrence.
    Neuro Oncol. 2020 May 27. pii: 5847629. doi: 10.1093.
    PubMed     Abstract available


  54. BARONI LV, Sampor C, Gonzalez A, Lubieniecki F, et al
    Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen.
    Neuro Oncol. 2020 May 15. pii: 5837622. doi: 10.1093.
    PubMed     Abstract available


  55. DI STEFANO AL, Picca A, Saragoussi E, Bielle F, et al
    Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions.
    Neuro Oncol. 2020 May 15. pii: 5837595. doi: 10.1093.
    PubMed     Abstract available


  56. SANTANA-CODINA N, Gonzalez J, Sierra A
    Reply to Letter to the Editor.
    Neuro Oncol. 2020;22:734-735.
    PubMed    


  57. BRANDSMA D, van den Bent MJB
    Quantification of leptomeningeal metastases from solid tumors remains a challenging issue.
    Neuro Oncol. 2020;22:592-593.
    PubMed    


  58. LOBBOUS M, Nabors LB
    A troublesome burden, the amplification of EGFR in glioblastoma!
    Neuro Oncol. 2020;22:594-595.
    PubMed    


  59. SCHELL M, Pfluger I, Brugnara G, Isensee F, et al
    Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Neuro Oncol. 2020 May 11. pii: 5836012. doi: 10.1093.
    PubMed     Abstract available


  60. GOLDMAN S, Pollack IF, Jakacki RI, Billups CA, et al
    Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
    Neuro Oncol. 2020 May 11. pii: 5836011. doi: 10.1093.
    PubMed     Abstract available


  61. GRIL B, Wei D, Zimmer AS, Robinson C, et al
    A HER2 Antibody Drug Conjugate Controls Growth of Breast Cancer Brain Metastases in Hematogenous Xenograft Models, with Heterogeneous Blood-Tumor Barrier Penetration Unlinked to a Passive Marker.
    Neuro Oncol. 2020 May 9. pii: 5835334. doi: 10.1093.
    PubMed     Abstract available


  62. ECKEL-PASSOW JE, Drucker KL, Kollmeyer TM, Kosel ML, et al
    Adult Diffuse Glioma GWAS by Molecular Subtype Identifies Variants in D2HGDH and FAM20C.
    Neuro Oncol. 2020 May 9. pii: 5835318. doi: 10.1093.
    PubMed     Abstract available


  63. BERNHARDT D, Wick W, Weiss SE, Sahgal A, et al
    Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
    Neuro Oncol. 2020 May 5. pii: 5829911. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  64. HANNA C, Kurian KM, Williams K, Watts C, et al
    Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
    Neuro Oncol. 2020 Apr 29. pii: 5826799. doi: 10.1093.
    PubMed     Abstract available


  65. TABRIZI S, Trippa L, Cagney D, Tanguturi S, et al
    A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.
    Neuro Oncol. 2020 Apr 27. pii: 5825707. doi: 10.1093.
    PubMed     Abstract available


  66. BALANA C, Vaz MA, Sepulveda JM, Mesia C, et al
    A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).
    Neuro Oncol. 2020 Apr 24. pii: 5824410. doi: 10.1093.
    PubMed     Abstract available


  67. WEN PY, Weller M, Lee EQ, Alexander BA, et al
    Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
    Neuro Oncol. 2020 Apr 24. pii: 5824407. doi: 10.1093.
    PubMed     Abstract available


  68. HUANG RY, Young RJ, Ellingson BM, Veeraraghavan H, et al
    Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment.
    Neuro Oncol. 2020 Apr 24. pii: 5824395. doi: 10.1093.
    PubMed     Abstract available


  69. YANG WB, Hsu CC, Hsu TI, Liou JP, et al
    Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.
    Neuro Oncol. 2020 Apr 24. pii: 5824394. doi: 10.1093.
    PubMed     Abstract available


  70. CLUCERU J, Nelson SJ, Wen Q, Phillips JJ, et al
    Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.
    Neuro Oncol. 2020 Apr 22. pii: 5823723. doi: 10.1093.
    PubMed     Abstract available


  71. DHALL G, O'Neil SH, Ji L, Haley K, et al
    Excellent Outcome of Young Children with Nodular Desmoplastic Medulloblastoma Treated on "Head Start" III: A Multi-Institutional, Prospective Clinical Trial.
    Neuro Oncol. 2020 Apr 18. pii: 5821791. doi: 10.1093.
    PubMed     Abstract available


  72. BELLAT V, Alcaina Y, Tung CH, Ting R, et al
    A Combined Approach of Convection-Enhanced Delivery of Peptide Nanofiber Reservoir to Prolong Delivery of DM1 for Diffuse Intrinsic Pontine Glioma Treatment.
    Neuro Oncol. 2020 Apr 17. pii: 5821265. doi: 10.1093.
    PubMed     Abstract available


  73. KRIEGER TG, Tirier SM, Park J, Jechow K, et al
    Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics.
    Neuro Oncol. 2020 Apr 16. pii: 5820825. doi: 10.1093.
    PubMed     Abstract available


  74. KEUNEN O, Niclou SP
    A prominent role for MR spectroscopy in the clinical management of brain tumors?
    Neuro Oncol. 2020 Apr 15. pii: 5820221. doi: 10.1093.
    PubMed    


  75. MOHILE NA, Blakeley JO, Gatson NTN, Hottinger AF, et al
    Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
    Neuro Oncol. 2020 Apr 11. pii: 5818980. doi: 10.1093.
    PubMed     Abstract available


  76. GUERRINI-ROUSSEAU L, Abbas R, Huybrechts S, Kieffer-Renaux V, et al
    Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.
    Neuro Oncol. 2020 Apr 8. pii: 5817932. doi: 10.1093.
    PubMed     Abstract available


  77. FUKUOKA K, Mamatjan Y, Tatevossian R, Zapotocky M, et al
    Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas.
    Neuro Oncol. 2020 Apr 3. pii: 5815300. doi: 10.1093.
    PubMed     Abstract available


  78. TABRIZI S, Shih HA
    The Path Forward for Radiation Therapy in the Management of Low-Grade Gliomas.
    Neuro Oncol. 2020 Apr 2. pii: 5815323. doi: 10.1093.
    PubMed    


  79. ULLRICH NJ, Prabhu SP, Reddy AT, Fisher MJ, et al
    A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study.
    Neuro Oncol. 2020 Apr 1. pii: 5814308. doi: 10.1093.
    PubMed     Abstract available


  80. LEE S, Latha K, Manyam G, Yang Y, et al
    Role of CX3CR1 Signaling in Malignant Transformation of Gliomas.
    Neuro Oncol. 2020 Apr 1. pii: 5814292. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  81. GODA JS, Dutta D, Krishna U, Goswami S, et al
    Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes: Mature data from a prospective trial in young patients with brain tumors.
    Neuro Oncol. 2020 Mar 30. pii: 5813654. doi: 10.1093.
    PubMed     Abstract available


  82. TAYLOR JT, Ellison S, Pandele A, Wood S, et al
    Actinomycin D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 30. pii: 5813520. doi: 10.1093.
    PubMed     Abstract available


  83. YOSHIDA GJ
    Comment on "GRP94 promotes brain metastasis by engaging pro-survival autophagy".
    Neuro Oncol. 2020 Mar 27. pii: 5812835. doi: 10.1093.
    PubMed    


  84. FEDERICI L, Capelle L, Annereau M, Bielle F, et al
    5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.
    Neuro Oncol. 2020 Mar 26. pii: 5812065. doi: 10.1093.
    PubMed    


  85. PENG J, Zhou H, Tang O, Chang K, et al
    Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
    Neuro Oncol. 2020 Mar 26. pii: 5811685. doi: 10.1093.
    PubMed     Abstract available


  86. SONG J, Kadaba P, Kravitz A, Hormigo A, et al
    Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2020 Mar 20. pii: 5810282. doi: 10.1093.
    PubMed     Abstract available


  87. GILL CM, Loewenstern J, Rutland JW, Arib H, et al
    Recurrent IDH Mutations in High-Grade Meningioma.
    Neuro Oncol. 2020 Mar 17. pii: 5808805. doi: 10.1093.
    PubMed    


  88. BAILEY CP, Figueroa M, Gangadharan A, Yang Y, et al
    Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG).
    Neuro Oncol. 2020 Mar 13. pii: 5804621. doi: 10.1093.
    PubMed     Abstract available


  89. MATHUR R, Zhang Y, Grimmer MR, Hong C, et al
    MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
    Neuro Oncol. 2020 Mar 13. pii: 5804625. doi: 10.1093.
    PubMed     Abstract available


  90. PUDUVALLI VK, Wu J, Yuan Y, Armstrong TS, et al
    A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 13. pii: 5804658. doi: 10.1093.
    PubMed     Abstract available


  91. GORELYSHEV A, Mazerkina N, Medvedeva O, Vasilyev E, et al
    Second-hit APC mutation in a familial adamantinomatous craniopharyngioma.
    Neuro Oncol. 2020 Mar 12. pii: 5805241. doi: 10.1093.
    PubMed    


  92. EBERHART C
    Astrocytes - New Stars In The Medulloblastoma Firmament.
    Neuro Oncol. 2020 Mar 11. pii: 5802783. doi: 10.1093.
    PubMed    


  93. KHATUA S, Cooper LJN, Sandberg DI, Ketonen L, et al
    Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma.
    Neuro Oncol. 2020 Mar 10. pii: 5802287. doi: 10.1093.
    PubMed     Abstract available


  94. LAMBA N, Mehanna E, Kearney RB, Catalano PJ, et al
    Racial disparities in supportive medication use among older patients with brain metastases: A population-based analysis.
    Neuro Oncol. 2020 Mar 9. pii: 5800995. doi: 10.1093.
    PubMed     Abstract available


  95. LIU CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, et al
    Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine.
    Neuro Oncol. 2020 Mar 5. pii: 5781186. doi: 10.1093.
    PubMed     Abstract available


  96. SIDDAWAY R, Hawkins C
    Modeling DIPG in the mouse brainstem.
    Neuro Oncol. 2020;22:307-308.
    PubMed    


    February 2020
  97. STOECKLEIN VM, Stoecklein S, Galie F, Ren J, et al
    Resting-state fMRI Detects Alterations in Whole Brain Connectivity Related to Tumor Biology in Glioma Patients.
    Neuro Oncol. 2020 Feb 28. pii: 5764143. doi: 10.1093.
    PubMed     Abstract available


  98. JIANG H, Yang K, Ren X, Cui Y, et al
    Retraction notice: Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
    Neuro Oncol. 2020 Feb 25. pii: 5756150. doi: 10.1093.
    PubMed    


  99. LIM M, Pant A
    Understanding innate immune response in Glioblastoma in search for a way forward.
    Neuro Oncol. 2020 Feb 22. pii: 5751793. doi: 10.1093.
    PubMed    


  100. HIMES BT, Peterson TE, de Mooij T, Garcia MLMC, et al
    The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Neuro Oncol. 2020 Feb 21. pii: 5742588. doi: 10.1093.
    PubMed     Abstract available


  101. MENDEZ FM, Nunez FJ, Garcia-Fabiani MB, Haase S, et al
    Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Neuro Oncol. 2020;22:195-206.
    PubMed     Abstract available


  102. BALASUBRAMANIYAN V, Bhat K
    Targeting pyrimidine metabolism for glioblastoma therapy.
    Neuro Oncol. 2020;22:169-170.
    PubMed    



  103. Corrigendum to Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2020 Feb 18. pii: 5740122. doi: 10.1093.
    PubMed    


  104. EATON BR, Goldberg S, Tarbell NJ, Lawell MP, et al
    Long-term Health Related Quality of Life in Pediatric Brain Tumor Survivors Treated with Proton Radiotherapy at <4 Years of Age.
    Neuro Oncol. 2020 Feb 17. pii: 5737810. doi: 10.1093.
    PubMed     Abstract available


  105. MUNSTERBERG J, Loreth D, Brylka L, Werner S, et al
    ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.
    Neuro Oncol. 2020 Feb 17. pii: 5737760. doi: 10.1093.
    PubMed     Abstract available


  106. PACKER RJ, Iavarone A, Jones DTW, Blakeley JO, et al
    Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference.
    Neuro Oncol. 2020 Feb 14. pii: 5736008. doi: 10.1093.
    PubMed     Abstract available


  107. FRITAH S, Niclou SP
    Dual blockade of STAT3 and EGFR, a key to unlock drug resistance in Glioblastoma?
    Neuro Oncol. 2020 Feb 14. pii: 5736011. doi: 10.1093.
    PubMed    


  108. TIWARI V, Daoud EV, Hatanpaa KJ, Gao A, et al
    Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.
    Neuro Oncol. 2020 Feb 14. pii: 5735772. doi: 10.1093.
    PubMed     Abstract available


  109. SASTRY NG, Wan X, Huang T, Alvarez AA, et al
    LY6K Promotes Glioblastoma Tumorigenicity via CAV-1-Mediated ERK1/2 Signaling Enhancement.
    Neuro Oncol. 2020 Feb 14. pii: 5735689. doi: 10.1093.
    PubMed     Abstract available


  110. ACHARYA S, Liu JF, Tatevossian RG, Chiang J, et al
    Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: An integrated clinicopathologic and molecular analysis.
    Neuro Oncol. 2020 Feb 13. pii: 5734990. doi: 10.1093.
    PubMed     Abstract available


  111. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM).
    Neuro Oncol. 2020 Feb 12. pii: 5734626. doi: 10.1093.
    PubMed     Abstract available


  112. ZINNHARDT B, Muther M, Roll W, Backhaus P, et al
    TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
    Neuro Oncol. 2020 Feb 12. pii: 5734268. doi: 10.1093.
    PubMed     Abstract available


  113. SPERDUTO PW, Mesko S, Li J, Cagney D, et al
    Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.
    Neuro Oncol. 2020 Feb 8. pii: 5731396. doi: 10.1093.
    PubMed     Abstract available


  114. DE VRIES F
    Letter regarding "Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning".
    Neuro Oncol. 2020 Feb 6. pii: 5728672. doi: 10.1093.
    PubMed    


  115. ROUX A, Pallud J, Saffroy R, Edjlali-Goujon M, et al
    High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.
    Neuro Oncol. 2020 Feb 6. pii: 5728472. doi: 10.1093.
    PubMed     Abstract available


  116. HAN MZ, Huang B, Ni SL, Wang J, et al
    A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort.
    Neuro Oncol. 2020 Feb 6. pii: 5728477. doi: 10.1093.
    PubMed    


  117. BAXTER PA, Su JM, Onar-Thomas A, Billups CA, et al
    A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2020 Feb 3. pii: 5721145. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  118. AZOULAY M, Chang SD, Gibbs IC, Hancock SL, et al
    A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.
    Neuro Oncol. 2020 Jan 31. pii: 5718251. doi: 10.1093.
    PubMed     Abstract available


  119. RIJNEN SJM, De Baene W, Rutten GM, Gehring K, et al
    In reply to the letter to the editor regarding 'Cognitive outcomes in meningioma patients undergoing surgery: Individual changes over time and predictors of late cognitive functioning'.
    Neuro Oncol. 2020 Jan 30. pii: 5718243. doi: 10.1093.
    PubMed    


  120. BREEN WG, Anderson SK, Carrero XW, Brown PD, et al
    Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
    Neuro Oncol. 2020 Jan 30. pii: 5718239. doi: 10.1093.
    PubMed     Abstract available


  121. LEE EQ, Weller M, Sul J, Bagley SJ, et al
    Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
    Neuro Oncol. 2020 Jan 24. pii: 5715205. doi: 10.1093.
    PubMed     Abstract available


  122. HULSBERGEN AFC, Claes A, Kavouridis VK, Ansaripour A, et al
    Subtype switching in breast cancer brain metastases: a multicenter analysis.
    Neuro Oncol. 2020 Jan 23. pii: 5714300. doi: 10.1093.
    PubMed     Abstract available


  123. MUSKENS IS, de Smith AJ, Zhang C, Hansen HM, et al
    Germline cancer predisposition variants and pediatric glioma: a population-based study in California.
    Neuro Oncol. 2020 Jan 23. pii: 5714303. doi: 10.1093.
    PubMed     Abstract available


  124. RAO G, Sonabend A, Heimberger AB
    Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients?
    Neuro Oncol. 2020 Jan 22. pii: 5714174. doi: 10.1093.
    PubMed    


  125. MOURAVIEV A, Detsky J, Sahgal A, Ruschin M, et al
    Use of Radiomics for the Prediction of Local Control of Brain Metastases After Stereotactic Radiosurgery.
    Neuro Oncol. 2020 Jan 20. pii: 5709657. doi: 10.1093.
    PubMed     Abstract available


  126. COMBA A, Dunn PJ, Argento AE, Kadiyala P, et al
    FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses.
    Neuro Oncol. 2020 Jan 17. pii: 5707582. doi: 10.1093.
    PubMed     Abstract available


  127. CIMINO PJ
    Analogous survival for patients with glioblastoma diagnosed by either histopathological or molecular features.
    Neuro Oncol. 2020 Jan 17. pii: 5707595. doi: 10.1093.
    PubMed    


  128. POPOVSKI D, Huang A
    Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies.
    Neuro Oncol. 2020;22:3-4.
    PubMed    


  129. TRIFILETTI DM, Brown PD
    Leptomeningeal disease following local brain irradiation: a new frontier.
    Neuro Oncol. 2020;22:5-6.
    PubMed    


  130. TERABE M, Gilbert MR
    Another layer of immune complication in glioblastoma: ICOS-ICOSL.
    Neuro Oncol. 2020 Jan 7. pii: 5697440. doi: 10.1093.
    PubMed    


  131. LAMBA N, Kearney RB, Mehanna E, Catalano PJ, et al
    Utility of claims data for identification of date of diagnosis of brain metastases.
    Neuro Oncol. 2020 Jan 6. pii: 5697047. doi: 10.1093.
    PubMed    


  132. PATEL RR, Verma V, Miller AB, Lin TA, et al
    Exclusion of Patients with Brain Metastases from Cancer Clinical Trials.
    Neuro Oncol. 2020 Jan 4. pii: 5695909. doi: 10.1093.
    PubMed    


    December 2019
  133. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth and enhances survival in mouse models in vivo.
    Neuro Oncol. 2019 Dec 28. pii: 5688710. doi: 10.1093.
    PubMed     Abstract available


  134. NASSIRI F, Zadeh G
    How should we manage incidental meningiomas?
    Neuro Oncol. 2019 Dec 25. pii: 5686813. doi: 10.1093.
    PubMed    


  135. XUE J, Wang B, Ming Y, Liu X, et al
    Deep-learning-based Detection and Segmentation-assisted Management on Brain Metastases.
    Neuro Oncol. 2019 Dec 23. pii: 5684915. doi: 10.1093.
    PubMed     Abstract available


  136. LANGEN KJ, Galldiks N, Lohmann P
    Combined FET PET/ADC mapping: improved imaging of glioma infiltration?
    Neuro Oncol. 2019 Dec 20. pii: 5681898. doi: 10.1093.
    PubMed    


  137. HUANG RY, Guenette JP
    Non-invasive Diagnosis of H3 K27M Mutant Midline Glioma.
    Neuro Oncol. 2019 Dec 20. pii: 5681667. doi: 10.1093.
    PubMed    


  138. RUDA R, Soffietti R
    Does an Optimal Management of Brain Metastases from Oncogenic-Driver Non-Small Cell Lung Cancer Exist?
    Neuro Oncol. 2019 Dec 20. pii: 5681666. doi: 10.1093.
    PubMed    


  139. HAIDER AS, van den Bent M, Wen PY, Vogelbaum MA, et al
    Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort.
    Neuro Oncol. 2019 Dec 17. pii: 5679607. doi: 10.1093.
    PubMed     Abstract available


  140. CLOUGHESY TF, Brenner A, de Groot JF, Butowski NA, et al
    A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
    Neuro Oncol. 2019 Dec 17. pii: 5679576. doi: 10.1093.
    PubMed     Abstract available


  141. BRENNER AJ, Peters KB, Vredenburgh J, Bokstein F, et al
    Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
    Neuro Oncol. 2019 Dec 17. pii: 5679561. doi: 10.1093.
    PubMed     Abstract available


  142. ARNOLD A, Yuan M, Price A, Harris L, et al
    Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Neuro Oncol. 2019 Dec 16. pii: 5679447. doi: 10.1093.
    PubMed     Abstract available


  143. ENE CI, Kreuser SA, Jung M, Zhang H, et al
    Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
    Neuro Oncol. 2019 Dec 3. pii: 5650878. doi: 10.1093.
    PubMed     Abstract available


  144. RUSS JB, Weiss WA
    Conversations on mutism: risk-stratification for cerebellar mutism based on medulloblastoma subtype.
    Neuro Oncol. 2019 Dec 3. pii: 5650866. doi: 10.1093.
    PubMed    


    November 2019
  145. DAVIS FG, Smith TR, Gittleman HR, Ostrom QT, et al
    Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.
    Neuro Oncol. 2019 Nov 30. pii: 5648949. doi: 10.1093.
    PubMed    


  146. CARROLL SL, Longo JF
    Salinomycin targets the genome of radioresistant cells in glioblastomas.
    Neuro Oncol. 2019 Nov 30. pii: 5648122. doi: 10.1093.
    PubMed    


  147. ANEJA S, Omuro A
    Imaging biomarkers for brain metastases: more than meets the eye.
    Neuro Oncol. 2019 Nov 28. pii: 5645031. doi: 10.1093.
    PubMed    


  148. CAM M, Charan M, Welker AM, Dravid P, et al
    DeltaNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
    Neuro Oncol. 2019 Nov 25. pii: 5640296. doi: 10.1093.
    PubMed     Abstract available


  149. DE GROOT J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, et al
    Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
    Neuro Oncol. 2019 Nov 22. pii: 5637917. doi: 10.1093.
    PubMed     Abstract available


  150. GEHRING K, Stuiver MM, Visser E, Kloek C, et al
    A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma: a proof of concept.
    Neuro Oncol. 2019 Nov 21. pii: 5637916. doi: 10.1093.
    PubMed     Abstract available


  151. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma.
    Neuro Oncol. 2019 Nov 20. pii: 5634209. doi: 10.1093.
    PubMed     Abstract available


  152. LIU H, Sun Y, O'Brien JA, Franco-Barraza J, et al
    Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.
    Neuro Oncol. 2019 Nov 15. pii: 5626144. doi: 10.1093.
    PubMed     Abstract available


  153. CAPDEVIELLE C, Desplat A, Charpentier J, Saggliocco F, et al
    HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.
    Neuro Oncol. 2019 Nov 10. pii: 5618834. doi: 10.1093.
    PubMed     Abstract available


  154. DRUMM MR, Dixit KS, Grimm S, Kumthekar P, et al
    Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2019 Nov 10. pii: 5618827. doi: 10.1093.
    PubMed     Abstract available


  155. ARRILLAGA-ROMANY I, Odia Y, Prabhu VV, Tarapore RS, et al
    Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Neuro Oncol. 2019 Nov 8. pii: 5614983. doi: 10.1093.
    PubMed     Abstract available


  156. COOMANS MB, Dirven L, Aaronson NK, Baumert BG, et al
    Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
    Neuro Oncol. 2019;21:1447-1457.
    PubMed     Abstract available


  157. WEI J, Chen P, Gupta P, Ott M, et al
    Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications.
    Neuro Oncol. 2019 Nov 3. pii: 5611251. doi: 10.1093.
    PubMed     Abstract available


  158. DAS A, Ramaswamy V
    Less treatment for Wingless Medulloblastoma: germline data re-emphasizes this.
    Neuro Oncol. 2019 Nov 3. pii: 5611252. doi: 10.1093.
    PubMed    


  159. FAN Q, An Z, Wong RA, Luo X, et al
    Betacellulin drives therapy-resistance in glioblastoma.
    Neuro Oncol. 2019 Nov 3. pii: 5611241. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  160. VICTOR RR, Malta TM, Seki T, Lita A, et al
    Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas.
    Neuro Oncol. 2019 Oct 30. pii: 5609197. doi: 10.1093.
    PubMed     Abstract available


  161. SAUNDERS CN, Cornish AJ, Kinnersley B, Law PJ, et al
    Lack of association between modifiable exposures and glioma risk: A Mendelian randomisation analysis.
    Neuro Oncol. 2019 Oct 30. pii: 5609347. doi: 10.1093.
    PubMed     Abstract available


  162. BALASUBRAMANIAN SK, Sharma M, Venur VA, Schmitt P, et al
    Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Neuro Oncol. 2019 Oct 24. pii: 5606822. doi: 10.1093.
    PubMed     Abstract available


  163. PATEL SK, Hartley RM, Wei X, Furnish R, et al
    Generation of diffuse intrinsic pontine glioma mouse models by brainstem targeted in utero electroporation.
    Neuro Oncol. 2019 Oct 22. pii: 5602255. doi: 10.1093.
    PubMed     Abstract available


  164. YOGANANDA CGB, Shah BR, Vejdani-Jahromi M, Nalawade SS, et al
    A Novel Fully Automated Mri-Based Deep Learning Method for Classification of Idh Mutation Status in Brain Gliomas.
    Neuro Oncol. 2019 Oct 22. pii: 5602247. doi: 10.1093.
    PubMed     Abstract available


  165. SANTANA-CODINA N, Muixi L, Foj R, Sanz-Pamplona R, et al
    GRP94 promotes brain metastasis by engaging pro-survival autophagy.
    Neuro Oncol. 2019 Oct 22. pii: 5602253. doi: 10.1093.
    PubMed     Abstract available


  166. TESILEANU CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, et al
    Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Neuro Oncol. 2019 Oct 22. pii: 5602222. doi: 10.1093.
    PubMed     Abstract available


  167. IWATA R, Lee JH, Hayashi M, Dianzani U, et al
    ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma.
    Neuro Oncol. 2019 Oct 22. pii: 5601905. doi: 10.1093.
    PubMed     Abstract available


  168. PLATTEN M
    Driving mesenchymal transition in glioblastoma.
    Neuro Oncol. 2019 Oct 19. pii: 5599736. doi: 10.1093.
    PubMed    


  169. JOHANNESSEN TA, Bjerkvig R
    A new chance for EGFR inhibition in glioblastoma?
    Neuro Oncol. 2019 Oct 19. pii: 5599734. doi: 10.1093.
    PubMed    


  170. GITTLEMAN H, Sloan AE, Barnholtz-Sloan JS
    An independently validated survival nomogram for lower grade glioma.
    Neuro Oncol. 2019 Oct 17. pii: 5588962. doi: 10.1093.
    PubMed     Abstract available


  171. BHATIA A, Birger M, Veeraraghavan H, Um H, et al
    MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
    Neuro Oncol. 2019 Oct 17. pii: 5588961. doi: 10.1093.
    PubMed     Abstract available


  172. IJAZ H, Koptyra M, Gaonkar KS, Rokita JL, et al
    Pediatric High Grade Glioma Resources from the Children's Brain Tumor Tissue Consortium (Cbttc).
    Neuro Oncol. 2019 Oct 15. pii: 5588066. doi: 10.1093.
    PubMed    


  173. ISLIM AI, Kolamunnage-Dona R, Mohan M, Moon RDC, et al
    A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.
    Neuro Oncol. 2019 Oct 11. pii: 5585790. doi: 10.1093.
    PubMed     Abstract available


  174. RUBIN JB, Schlaggar BL
    To each, his/her own.
    Neuro Oncol. 2019;21:1217-1218.
    PubMed    


  175. WU CY, Chen CH, Lin CY, Feng LY, et al
    CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase-2.
    Neuro Oncol. 2019 Oct 8. pii: 5583889. doi: 10.1093.
    PubMed     Abstract available


  176. KOMORI T
    The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community.
    Neuro Oncol. 2019 Oct 5. pii: 5581618. doi: 10.1093.
    PubMed    


    September 2019
  177. SU X, Chen N, Sun H, Liu Y, et al
    Automated Machine Learning Based on Radiomics Features Predicts H3 K27M Mutation in Midline Gliomas of the Brain.
    Neuro Oncol. 2019 Sep 29. pii: 5575985. doi: 10.1093.
    PubMed     Abstract available


  178. FU Y, Wang D, Wang H, Cai M, et al
    TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis and a growth-promoting metabolic shift towards glycolysis in glioblastoma.
    Neuro Oncol. 2019 Sep 29. pii: 5575982. doi: 10.1093.
    PubMed     Abstract available


  179. RIVERO-HINOJOSA S, Kinney N, Garner HR, Rood BR, et al
    Germline Microsatellite Genotypes Differentiate Children with Medulloblastoma.
    Neuro Oncol. 2019 Sep 28. pii: 5575474. doi: 10.1093.
    PubMed     Abstract available


  180. VERBURG N, Koopman T, Yaqub MM, Hoekstra OS, et al
    Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Neuro Oncol. 2019 Sep 24. pii: 5573318. doi: 10.1093.
    PubMed     Abstract available


  181. CORROYER-DULMONT A, Valable S, Falzone N, Frelin-Labalme AM, et al
    VCAM-1 Targeted Alpha-Particle Therapy for Early Brain Metastases.
    Neuro Oncol. 2019 Sep 20. pii: 5571872. doi: 10.1093.
    PubMed     Abstract available


  182. TANNOUS BA, Badr CE
    An allosteric inhibitor of SHP2 effectively targets PDGFRalpha-driven glioblastoma.
    Neuro Oncol. 2019 Sep 17. pii: 5570971. doi: 10.1093.
    PubMed    


  183. MAJD N, Weathers SP, de Groot J
    Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?
    Neuro Oncol. 2019 Sep 13. pii: 5568470. doi: 10.1093.
    PubMed    


  184. WONG D, Yip S
    Finding a four-leaf clover - identifying long term survivors in IDH- wildtype glioblastoma.
    Neuro Oncol. 2019 Sep 12. pii: 5568014. doi: 10.1093.
    PubMed    


  185. GALLDIKS N, Verger A, Zaragori T, Unterrainer M, et al
    Comment on "Hypometabolic gliomas on FET-PET - Is there an inverted U-curve for survival?", Kamson 2019, Neuro-Oncology.
    Neuro Oncol. 2019 Sep 10. pii: 5567232. doi: 10.1093.
    PubMed    


  186. ECHIZENYA S, Ishii Y, Kitazawa S, Tanaka T, et al
    Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.
    Neuro Oncol. 2019 Sep 10. pii: 5566464. doi: 10.1093.
    PubMed     Abstract available


  187. WOLPERT F, Lareida A, Terziev R, Grossenbacher B, et al
    Risk factors for the development of epilepsy in patients with brain metastasis.
    Neuro Oncol. 2019 Sep 10. pii: 5566445. doi: 10.1093.
    PubMed     Abstract available


  188. ELLINGSON BM
    On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas.
    Neuro Oncol. 2019 Sep 6. pii: 5561587. doi: 10.1093.
    PubMed    


  189. BASHIR A, Mathilde Jacobsen S, Molby Henriksen O, Broholm H, et al
    Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Neuro Oncol. 2019 Sep 6. pii: 5564094. doi: 10.1093.
    PubMed     Abstract available


  190. ZHANG S, Liao K, Miao Z, Wang Q, et al
    CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5.
    Neuro Oncol. 2019 Sep 4. pii: 5560150. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  191. LIM YC, Ensbey KS, Offenhauser C, D'Souza RCJ, et al
    Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore.
    Neuro Oncol. 2019 Aug 30. pii: 5556892. doi: 10.1093.
    PubMed     Abstract available


  192. JIANG H, Yang K, Ren X, Cui Y, et al
    Diffuse midline glioma with an H3 K27M mutation: A comparison integrating the clinical, radiological, molecular features between adult and pediatric patients.
    Neuro Oncol. 2019 Aug 24. pii: 5554271. doi: 10.1093.
    PubMed     Abstract available


  193. FOSTER JB, Madsen PJ, Hegde M, Ahmed N, et al
    Immunotherapy for pediatric brain tumors: past and present.
    Neuro Oncol. 2019 Aug 24. pii: 5554145. doi: 10.1093.
    PubMed     Abstract available


  194. SURUN A, Varlet P, Brugieres L, Lacour B, et al
    Medulloblastomas associated with APC germline pathogenic variant share the good prognosis of CTNNB1 mutated medulloblastomas.
    Neuro Oncol. 2019 Aug 23. pii: 5554125. doi: 10.1093.
    PubMed     Abstract available


  195. JABARKHEEL R, Amayiri N, Yecies D, Huang Y, et al
    Molecular correlates of cerebellar mutism syndrome in medulloblastoma.
    Neuro Oncol. 2019 Aug 23. pii: 5554118. doi: 10.1093.
    PubMed     Abstract available


  196. GALLDIKS N, Kocher M, Ceccon G, Werner JM, et al
    Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression.
    Neuro Oncol. 2019 Aug 22. pii: 5553498. doi: 10.1093.
    PubMed     Abstract available


  197. SATTERLEE AB, Dunn DE, Lo DC, Khagi S, et al
    Tumoricidal Stem Cell Therapy Enables Killing in Novel Hybrid Models of Heterogeneous Glioblastoma.
    Neuro Oncol. 2019 Aug 17. pii: 5550912. doi: 10.1093.
    PubMed     Abstract available


  198. VARLET P, Le Teuff G, Le Deley MC, Giangaspero F, et al
    WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
    Neuro Oncol. 2019 Aug 16. pii: 5550833. doi: 10.1093.
    PubMed     Abstract available


  199. NGUYEN TK, Sahgal A, Detsky J, Atenafu EG, et al
    Predictors of Leptomeningeal Disease Following Hypofractionated Stereotactic Radiotherapy for Intact and Resected Brain Metastases.
    Neuro Oncol. 2019 Aug 15. pii: 5550117. doi: 10.1093.
    PubMed     Abstract available


  200. WIRSCHING HG, Arora S, Zhang H, Szulzewsky F, et al
    Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9.
    Neuro Oncol. 2019 Aug 15. pii: 5550114. doi: 10.1093.
    PubMed    


  201. SONG Y, Jiang Y, Tao D, Wang Z, et al
    NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.
    Neuro Oncol. 2019 Aug 11. pii: 5545998. doi: 10.1093.
    PubMed     Abstract available


  202. SHEN H, Yu M, Tsoli M, Chang C, et al
    Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas.
    Neuro Oncol. 2019 Aug 9. pii: 5545641. doi: 10.1093.
    PubMed     Abstract available


  203. FURTNER J, Genbrugge E, Gorlia T, Bendszus M, et al
    Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
    Neuro Oncol. 2019 Aug 1. pii: 5542781. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  204. GUO G, Gong K, Puliyapaddamba VT, Panchani N, et al
    Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
    Neuro Oncol. 2019 Jul 31. pii: 5541686. doi: 10.1093.
    PubMed     Abstract available


  205. WANG T, Qiu Y, Liang L, Zheng E, et al
    H3 K27M-mutant glioma: Clinical Characteristics and Outcomes.
    Neuro Oncol. 2019 Jul 29. pii: 5540063. doi: 10.1093.
    PubMed    


  206. YOUSSEF GC, Gomez-Manzano C, Sawaya R, Fueyo J, et al
    Antitumor immune response during glioma virotherapy.
    Neuro Oncol. 2019 Jul 26. pii: 5539565. doi: 10.1093.
    PubMed    


  207. BURGENSKE DM, Yang J, Decker PA, Kollmeyer TM, et al
    Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors.
    Neuro Oncol. 2019 Jul 26. pii: 5539012. doi: 10.1093.
    PubMed     Abstract available


  208. ARZT M, Monje M
    Comment on "Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia", Guo et al. 2019, Neuro-Oncology.
    Neuro Oncol. 2019 Jul 13. pii: 5532273. doi: 10.1093.
    PubMed    


  209. OSTROM QT, Adel Fahmideh M, Cote DJ, Muskens IS, et al
    Risk Factors For Childhood And Adult Primary Brain Tumors.
    Neuro Oncol. 2019 Jul 12. pii: 5532012. doi: 10.1093.
    PubMed     Abstract available


  210. APPAY R, Dehais C, Maurage CA, Alentorn A, et al
    CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Neuro Oncol. 2019 Jul 12. pii: 5531923. doi: 10.1093.
    PubMed     Abstract available


  211. KAMSON DO
    Hypometabolic gliomas on FET-PET - Is there an inverted U-curve for survival?
    Neuro Oncol. 2019 Jul 5. pii: 5529276. doi: 10.1093.
    PubMed    


  212. CUI J, Zhang Q, Song Q, Wang H, et al
    Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.
    Neuro Oncol. 2019 Jul 4. pii: 5528786. doi: 10.1093.
    PubMed     Abstract available


  213. HORBINSKI C, Ligon KL, Brastianos P, Huse JT, et al
    The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
    Neuro Oncol. 2019 Jul 4. pii: 5528614. doi: 10.1093.
    PubMed     Abstract available


  214. HOLDHOFF M
    Discovery of predictive biomarkers in malignant gliomas.
    Neuro Oncol. 2019 Jul 4. pii: 5528181. doi: 10.1093.
    PubMed    


    June 2019
  215. BECHER OJ
    HDAC inhibitors to the rescue in Sonic Hedgehog Medulloblastoma.
    Neuro Oncol. 2019 Jun 26. pii: 5523731. doi: 10.1093.
    PubMed    


  216. SANG Y, Hou Y, Cheng R, Zheng L, et al
    Targeting PDGFRalpha-activated Glioblastoma through Specific Inhibition of SHP-2-mediated Signaling.
    Neuro Oncol. 2019 Jun 21. pii: 5522282. doi: 10.1093.
    PubMed     Abstract available


  217. CHANG K, Beers AL, Bai HX, Brown JM, et al
    Automatic assessment of glioma burden: A deep learning algorithm for fully automated volumetric and bi-dimensional measurement.
    Neuro Oncol. 2019 Jun 13. pii: 5514498. doi: 10.1093.
    PubMed     Abstract available


  218. IPPEN FM, Grosch JK, Subramanian M, Kuter BM, et al
    Targeting the PI3K/Akt/mTOR-pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Neuro Oncol. 2019 Jun 7. pii: 5512506. doi: 10.1093.
    PubMed     Abstract available


  219. LEE EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, et al
    Barriers to Accrual and Enrollment in Brain Tumor Trials.
    Neuro Oncol. 2019 Jun 7. pii: 5513026. doi: 10.1093.
    PubMed     Abstract available


  220. NASSIRI F, Mamatjan Y, Suppiah S, Badhiwala JH, et al
    DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
    Neuro Oncol. 2019 Jun 3. pii: 5510481. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  221. EBERHART CG
    A fox with many faces: FOXR2 and embryonal brain tumors.
    Neuro Oncol. 2019 May 31. pii: 5509373. doi: 10.1093.
    PubMed    


  222. CHOI KS, Choi SH, Jeong B
    Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Neuro Oncol. 2019 May 24. pii: 5498696. doi: 10.1093.
    PubMed     Abstract available


  223. ZHAO SG, Yu M, Spratt DE, Chang SL, et al
    Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
    Neuro Oncol. 2019 May 23. pii: 5497946. doi: 10.1093.
    PubMed     Abstract available


  224. BLEDSOE JC, Breiger D, Breiger M, Shonka S, et al
    Differential Trajectories of Neurocognitive Functioning in Females versus Males Following Treatment for Pediatric Brain Tumors.
    Neuro Oncol. 2019 May 23. pii: 5498067. doi: 10.1093.
    PubMed     Abstract available


  225. CORREA DD, Satagopan J, Martin A, Braun E, et al
    Genetic Variants and Cognitive Functions in Patients with Brain Tumors.
    Neuro Oncol. 2019 May 23. pii: 5498070. doi: 10.1093.
    PubMed     Abstract available


  226. PAK E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, et al
    A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Neuro Oncol. 2019 May 16. pii: 5490616. doi: 10.1093.
    PubMed     Abstract available


  227. JALALI R, Goda JS
    Proton beam therapy in pediatric brain tumor patients: Improved radiation delivery techniques improve neurocognitive outcomes.
    Neuro Oncol. 2019 May 13. pii: 5488773. doi: 10.1093.
    PubMed    


  228. GALLDIKS N, Unterrainer M, Judov N, Stoffels G, et al
    Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET - Clinical relevance in glioma patients.
    Neuro Oncol. 2019 May 11. pii: 5488073. doi: 10.1093.
    PubMed     Abstract available


  229. PAPAIOANNOU MD, Djuric U, Kao J, Karimi S, et al
    Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns.
    Neuro Oncol. 2019 May 11. pii: 5488088. doi: 10.1093.
    PubMed     Abstract available


  230. ARMSTRONG FD
    Commentary: Implications of health status, health-related quality of life, and socio-economic outcomes in survivors of childhood brain tumor survivors.
    Neuro Oncol. 2019 May 11. pii: 5488084. doi: 10.1093.
    PubMed    


  231. YOO JY, Swanner J, Otani Y, Nair M, et al
    oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
    Neuro Oncol. 2019 May 7. pii: 5486519. doi: 10.1093.
    PubMed     Abstract available


  232. JONES J
    Glioblastoma single extracellular vesicle analysis profiles: wading into new oceans of tumor data.
    Neuro Oncol. 2019;21:562-564.
    PubMed    


  233. WESSELING P
    The ABCs of molecular diagnostic testing of CNS tumors: acceptance, benefits, costs.
    Neuro Oncol. 2019;21:559-561.
    PubMed    


  234. YAO J, Chakhoyan A, Nathanson DA, Yong WH, et al
    Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
    Neuro Oncol. 2019 May 4. pii: 5485508. doi: 10.1093.
    PubMed     Abstract available


  235. VOGELBAUM MA, Yu HM
    Nodular Leptomeningeal Disease After Surgery for a Brain Metastasis - Should We Be Concerned?
    Neuro Oncol. 2019 May 3. pii: 5485425. doi: 10.1093.
    PubMed    


  236. GUO X, Pan Y, Gutmann DH
    Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.
    Neuro Oncol. 2019 May 3. pii: 5485427. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  237. DARDAUD LM, Bris C, Desquiret-Dumas V, Boisselier B, et al
    High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.
    Neuro Oncol. 2019 Apr 26. pii: 5480712. doi: 10.1093.
    PubMed    


  238. TZARIDIS T, Gepfner-Tuma I, Hirsch S, Skardelly M, et al
    Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
    Neuro Oncol. 2019 Apr 23. pii: 5476431. doi: 10.1093.
    PubMed    


  239. WALSH KM, Claus EB
    Diet and risk of glioma: targets for prevention remain elusive.
    Neuro Oncol. 2019 Apr 23. pii: 5476430. doi: 10.1093.
    PubMed    


  240. GREENALL SA, McKenzie M, Seminova E, Dolezal O, et al
    Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
    Neuro Oncol. 2019 Apr 19. pii: 5475297. doi: 10.1093.
    PubMed     Abstract available


  241. GROSS JP, Powell S, Zelko F, Hartsell W, et al
    Improved neuropsychological outcomes following proton therapy relative to x-ray therapy for pediatric brain tumor patients.
    Neuro Oncol. 2019 Apr 17. pii: 5475068. doi: 10.1093.
    PubMed     Abstract available


  242. ACHARYA S, Wu S, Ashford JM, Tinkle CL, et al
    Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study.
    Neuro Oncol. 2019 Apr 12. pii: 5447930. doi: 10.1093.
    PubMed     Abstract available


  243. RUDA R
    New developments and new dilemmas in lower-grade gliomas.
    Neuro Oncol. 2019 Apr 11. pii: 5440576. doi: 10.1093.
    PubMed    


  244. HOSSAIN JA, Latif MA, Ystaas LAR, Ninzima S, et al
    Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.
    Neuro Oncol. 2019 Apr 8. pii: 5431345. doi: 10.1093.
    PubMed     Abstract available


  245. MARISETTY AL, Lu L, Veo BL, Liu B, et al
    REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
    Neuro Oncol. 2019 Apr 6. pii: 5430241. doi: 10.1093.
    PubMed     Abstract available


  246. PLATTEN M
    How to integrate immunotherapy into standard of care in glioblastoma.
    Neuro Oncol. 2019 Apr 2. pii: 5425530. doi: 10.1093.
    PubMed    


    March 2019
  247. FINOCCHIARO G, Pellegatta S
    NG2/CSPG4 in glioblastoma: about flexibility.
    Neuro Oncol. 2019 Mar 28. pii: 5421177. doi: 10.1093.
    PubMed    


  248. TSANG DS, Edelstein K
    Late effects after childhood brain tumour treatment: It's not just about the radiation.
    Neuro Oncol. 2019 Mar 28. pii: 5421189. doi: 10.1093.
    PubMed    


  249. CHANG SM, Messersmith H, Ahluwalia M, Andrews D, et al
    Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.
    Neuro Oncol. 2019;21:424-427.
    PubMed     Abstract available


  250. KIERAN MW, Goumnerova L, Manley P, Chi SN, et al
    Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.
    Neuro Oncol. 2019;21:537-546.
    PubMed     Abstract available


  251. ICHIMURA K
    TERT promoter mutation as a diagnostic marker for diffuse gliomas.
    Neuro Oncol. 2019 Mar 10. pii: 5372924. doi: 10.1093.
    PubMed    


  252. SAIT SF, Karajannis MA
    The new kid on the block: suicide gene therapy to modulate cancer immunosurveillance for children with high-risk malignant brain tumors.
    Neuro Oncol. 2019 Mar 10. pii: 5372925. doi: 10.1093.
    PubMed    


  253. AKAMANDISA MP, Nie K, Nahta R, Hambardzumyan D, et al
    Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2019 Mar 10. pii: 5372846. doi: 10.1093.
    PubMed     Abstract available


  254. PRABHU RS, Turner BE, Asher AL, Marcrom SR, et al
    A Multi-Institutional Analysis of Presentation and Outcomes for Leptomeningeal Disease Recurrence After Surgical Resection and Radiosurgery for Brain Metastases.
    Neuro Oncol. 2019 Mar 4. pii: 5368947. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  255. MIKLJA Z, Pasternak A, Stallard S, Nicolaides T, et al
    Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
    Neuro Oncol. 2019 Feb 26. pii: 5364813. doi: 10.1093.
    PubMed     Abstract available


  256. KOTECHA R, Kim JM, Miller JA, Juloori A, et al
    The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.
    Neuro Oncol. 2019 Feb 23. pii: 5364051. doi: 10.1093.
    PubMed     Abstract available


  257. SCHOLTES C, Baust K, Weinhold L, Creutzig U, et al
    Health status, Health-Related Quality of Life and Socio-economic Outcome in Childhood Brain Tumor Survivors: a German Cohort Study.
    Neuro Oncol. 2019 Feb 22. pii: 5355656. doi: 10.1093.
    PubMed     Abstract available


  258. BARNHOLTZ-SLOAN JS
    Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!
    Neuro Oncol. 2019;21:291-292.
    PubMed    


  259. BJERKVIG R, Thorsen F
    Glioblastoma: a prognostic value of AMT-PET?
    Neuro Oncol. 2019;21:146-147.
    PubMed    


  260. YU L, Xu J, Liu J, Zhang H, et al
    The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.
    Neuro Oncol. 2019 Feb 12. pii: 5316233. doi: 10.1093.
    PubMed     Abstract available


  261. SCHIFF D, van den Bent M, Vogelbaum MA, Wick W, et al
    Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.
    Neuro Oncol. 2019 Feb 8. pii: 5310249. doi: 10.1093.
    PubMed     Abstract available


  262. LUDMIR EB, Mahajan A, Paulino AC, Jones JY, et al
    Increased Risk of Pseudoprogression among Pediatric Low-Grade Glioma Patients Treated with Proton versus Photon Radiotherapy.
    Neuro Oncol. 2019 Feb 7. pii: 5308917. doi: 10.1093.
    PubMed     Abstract available


  263. RIJNEN SJM, Meskal I, Bakker M, De Baene W, et al
    Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning.
    Neuro Oncol. 2019 Feb 7. pii: 5308915. doi: 10.1093.
    PubMed     Abstract available


  264. KAHALLEY LS, Ris MD, Mahajan A, Okcu MF, et al
    Prospective, Longitudinal Comparison of Neurocognitive Change in Pediatric Brain Tumor Patients Treated with Proton Radiotherapy versus Surgery Only.
    Neuro Oncol. 2019 Feb 7. pii: 5308916. doi: 10.1093.
    PubMed     Abstract available


  265. KIM JM, Miller JA, Kotecha R, Chao ST, et al
    Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
    Neuro Oncol. 2019 Feb 6. pii: 5288601. doi: 10.1093.
    PubMed     Abstract available


  266. BRANZOLI F, Pontoizeau C, Tchara L, Di Stefano AL, et al
    Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.
    Neuro Oncol. 2019 Feb 6. pii: 5308111. doi: 10.1093.
    PubMed     Abstract available


  267. PIGEON H, Peres EA, Truillet C, Jego B, et al
    TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.
    Neuro Oncol. 2019 Feb 5. pii: 5307172. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  268. KUAN AS, Green J, Kitahara CM, Berrington de Gonzalez A, et al
    Diet and risk of glioma: combined analysis of three large prospective studies in the UK and USA.
    Neuro Oncol. 2019 Jan 23. pii: 5299220. doi: 10.1093.
    PubMed     Abstract available


  269. MILLER JJ, Loebel F, Juratli TA, Tummala SS, et al
    Accelerated progression of IDH mutant glioma after first recurrence.
    Neuro Oncol. 2019 Jan 22. pii: 5298917. doi: 10.1093.
    PubMed     Abstract available


  270. WENGER A, Ferreyra Vega S, Kling T, Olsson Bontell T, et al
    Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification.
    Neuro Oncol. 2019 Jan 22. pii: 5298599. doi: 10.1093.
    PubMed     Abstract available


  271. GATES EDH, Lin JS, Weinberg JS, Hamilton J, et al
    Guiding the First Biopsy in Glioma Patients using Estimated Ki67 Maps Derived from Magnetic Resonance Imaging: Conventional versus Advanced Imaging.
    Neuro Oncol. 2019 Jan 17. pii: 5290387. doi: 10.1093.
    PubMed     Abstract available


  272. HUANG RY, Bi WL, Griffith B, Kaufmann TJ, et al
    Imaging and diagnostic advances for intracranial meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Abstract available


  273. SUPPIAH S, Nassiri F, Bi WL, Dunn IF, et al
    Molecular and translational advances in meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Abstract available


  274. BRASTIANOS PK, Galanis E, Butowski N, Chan JW, et al
    Advances in multidisciplinary therapy for meningiomas.
    Neuro Oncol. 2019;21.
    PubMed     Abstract available


  275. NASSIRI F, Price B, Shehab A, Au K, et al
    Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life.
    Neuro Oncol. 2019;21.
    PubMed     Abstract available


  276. NASSIRI F, Tabatabai G, Aldape K, Zadeh G, et al
    Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas.
    Neuro Oncol. 2019;21.
    PubMed    


  277. WILLARD VW, Berlin KS, Conklin HM, Merchant TE, et al
    Trajectories of psychosocial and cognitive functioning in pediatric patients with brain tumors treated with radiation therapy.
    Neuro Oncol. 2019 Jan 8. pii: 5280722. doi: 10.1093.
    PubMed     Abstract available


  278. ECKEL-PASSOW JE, Decker PA, Kosel ML, Kollmeyer TM, et al
    Using germline variants to estimate glioma and subtype risks.
    Neuro Oncol. 2019 Jan 8. pii: 5280678. doi: 10.1093.
    PubMed     Abstract available


  279. MUSKENS IS, Wu AH, Porcel J, Cheng I, et al
    Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.
    Neuro Oncol. 2019 Jan 6. pii: 5274483. doi: 10.1093.
    PubMed     Abstract available


  280. GALLDIKS N, Langen KJ, Albert NL, Chamberlain M, et al
    PET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group.
    Neuro Oncol. 2019 Jan 5. pii: 5274178. doi: 10.1093.
    PubMed     Abstract available


  281. COLMAN H
    A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.
    Neuro Oncol. 2019;21:6-7.
    PubMed    


  282. COLMAN H
    A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.
    Neuro Oncol. 2019;21:6-7.
    PubMed    


    December 2018
  283. ZHI T, Jiang K, Xu X, Yu T, et al
    ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1.
    Neuro Oncol. 2018 Dec 24. pii: 5260093. doi: 10.1093.
    PubMed     Abstract available


  284. AL-MAYHANI T, Heywood R, Vemireddy V, Lathia JD, et al
    A Non-Hierarchical Organisation of Tumorigenic NG2 Cells in Glioblastoma promoted by EGFR.
    Neuro Oncol. 2018 Dec 22. pii: 5257356. doi: 10.1093.
    PubMed     Abstract available


  285. FRASER K, Jo A, Giedt J, Vinegoni C, et al
    Characterization of single microvesicles in plasma from glioblastoma patients.
    Neuro Oncol. 2018 Dec 17. pii: 5250654. doi: 10.1093.
    PubMed     Abstract available


  286. CLYMER J, Bandopadhayay P
    Old meet new-the path to combination treatments in pediatric low-grade gliomas.
    Neuro Oncol. 2018 Dec 11. pii: 5238696. doi: 10.1093.
    PubMed    


    November 2018
  287. NARITA Y, Arakawa Y, Yamasaki F, Nishikawa R, et al
    A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
    Neuro Oncol. 2018 Nov 30. pii: 5219198. doi: 10.1093.
    PubMed     Abstract available


  288. BALE TA, Jordan JT, Rapalino O, Ramamurthy N, et al
    Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.
    Neuro Oncol. 2018 Nov 28. pii: 5212363. doi: 10.1093.
    PubMed     Abstract available


  289. LUDMIR EB, Mandel JJ, McAleer MF, de Groot JF, et al
    Disparities along the glioblastoma clinical trials landscape.
    Neuro Oncol. 2018 Nov 26. pii: 5209731. doi: 10.1093.
    PubMed    


  290. DI STEFANO AL, Savatovsky J, Feuvret L, Villa C, et al
    CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.
    Neuro Oncol. 2018 Nov 23. pii: 5203543. doi: 10.1093.
    PubMed    


  291. HORBINSKI C
    Differences in molecular profiles of glioblastomas according to location.
    Neuro Oncol. 2018 Nov 15. pii: 5183524. doi: 10.1093.
    PubMed    


  292. SCHIFF D, de Groot JF
    Lower-grade gliomas: the wrong target for bevacizumab.
    Neuro Oncol. 2018;20:1559-1560.
    PubMed    


  293. SPERDUTO PW, Deegan BJ, Li J, Jethwa KR, et al
    Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.
    Neuro Oncol. 2018;20:1652-1660.
    PubMed     Abstract available


  294. EISEMANN T, Costa B, Harter PN, Wick W, et al
    Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
    Neuro Oncol. 2018 Nov 10. pii: 5168873. doi: 10.1093.
    PubMed     Abstract available


  295. PRABHU AH, Kant S, Kesarwani P, Ahmed K, et al
    Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.
    Neuro Oncol. 2018 Nov 10. pii: 5172259. doi: 10.1093.
    PubMed     Abstract available


  296. AQUILANTI E, Miller J, Santagata S, Cahill DP, et al
    Updates in prognostic markers for gliomas.
    Neuro Oncol. 2018;20.
    PubMed     Abstract available


    October 2018
  297. DIPLAS BH, Liu H, Yang R, Hansen LJ, et al
    Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
    Neuro Oncol. 2018 Oct 22. pii: 5140128. doi: 10.1093.
    PubMed     Abstract available


  298. JOHN F, Bosnyak E, Robinette NL, Amit-Yousif AJ, et al
    Multimodal Imaging-defined Subregions in Newly-diagnosed Glioblastoma: Impact on Overall Survival.
    Neuro Oncol. 2018 Oct 22. pii: 5140157. doi: 10.1093.
    PubMed     Abstract available


  299. DE LEEUW CN, Vogelbaum MA
    Supratotal Resection in Glioma: A Systematic Review.
    Neuro Oncol. 2018 Oct 15. pii: 5131643. doi: 10.1093.
    PubMed     Abstract available


  300. KORJA M, Raj R, Seppa K, Luostarinen T, et al
    Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland.
    Neuro Oncol. 2018 Oct 12. pii: 5127281. doi: 10.1093.
    PubMed     Abstract available


  301. ACHEY RL, Gittleman H, Schroer J, Khanna V, et al
    Non-malignant and malignant meningioma incidence and survival in the elderly from 2005-2015 using the Central Brain Tumor Registry of the United States.
    Neuro Oncol. 2018 Oct 6. pii: 5122860. doi: 10.1093.
    PubMed     Abstract available


  302. WICK W, Dettmer S, Berberich A, Kessler T, et al
    N2M2 (NOA20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Neuro Oncol. 2018 Oct 1. pii: 5113425. doi: 10.1093.
    PubMed     Abstract available


  303. BARAJAS RF JR, Hamilton BE, Schwartz D, McConnell HL, et al
    Combined Iron Oxide Nanoparticle Ferumoxytol and Gadolinium Contrast Enhanced MRI Defines Glioblastoma Pseudo-progression.
    Neuro Oncol. 2018 Oct 1. pii: 5113424. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  304. MORAES FY, Winter J, Atenafu EG, Dasgputa A, et al
    Outcomes following SRS for small- to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose.
    Neuro Oncol. 2018 Sep 28. pii: 5108534. doi: 10.1093.
    PubMed     Abstract available


  305. ZHANG H, Liao J, Zhang X, Zhao E, et al
    Sex difference of mutation clonality in diffuse glioma evolution.
    Neuro Oncol. 2018 Sep 25. pii: 5106960. doi: 10.1093.
    PubMed     Abstract available


  306. KORSHUNOV A, Sahm F, Zheludkova O, Golanov A, et al
    DNA-methylation profiling is a method of choice for molecular verification of pediatric WNT activated medulloblastomas.
    Neuro Oncol. 2018 Sep 25. pii: 5106618. doi: 10.1093.
    PubMed     Abstract available


  307. AJITHKUMAR T, Imbulgoda N, Rees E, Harris F, et al
    Uncommon low-grade brain tumors.
    Neuro Oncol. 2018 Sep 20. pii: 5104003. doi: 10.1093.
    PubMed     Abstract available


  308. POORE B, Yuan M, Arnold A, Price A, et al
    mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
    Neuro Oncol. 2018 Sep 18. pii: 5100756. doi: 10.1093.
    PubMed     Abstract available


  309. MANSOURI A, Hachem LD, Mansouri S, Nassiri F, et al
    MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
    Neuro Oncol. 2018 Sep 5. pii: 5090948. doi: 10.1093.
    PubMed     Abstract available


  310. YAMASHITA AS, da Costa Rosa M, Borodovsky A, Festuccia WT, et al
    Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide.
    Neuro Oncol. 2018 Sep 3. pii: 5089721. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  311. HENCH J, Bihl M, Bratic Hench I, Hoffmann P, et al
    Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics.
    Neuro Oncol. 2018 Aug 30. pii: 5087930. doi: 10.1093.
    PubMed    


  312. LIEBERMAN NAP, DeGolier K, Kovar HM, Davis A, et al
    Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy.
    Neuro Oncol. 2018 Aug 28. pii: 5085631. doi: 10.1093.
    PubMed     Abstract available


  313. JACOBS DI, Fukumura K, Bainbridge MN, Armstrong GN, et al
    Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series.
    Neuro Oncol. 2018 Aug 24. pii: 5079134. doi: 10.1093.
    PubMed     Abstract available


  314. SVENSSON F, Westerman B, Wurdinger T, Bailey D, et al
    GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.
    Neuro Oncol. 2018 Aug 20. pii: 5076955. doi: 10.1093.
    PubMed    


  315. HUANG RY, Bi WL, Weller M, Kaley T, et al
    Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology (RANO) Working Group.
    Neuro Oncol. 2018 Aug 18. pii: 5076187. doi: 10.1093.
    PubMed     Abstract available


  316. OSTROM QT, Coleman W, Huang W, Rubin JB, et al
    Sex-specific gene and pathway modeling of inherited glioma risk.
    Neuro Oncol. 2018 Aug 14. pii: 5073373. doi: 10.1093.
    PubMed     Abstract available


  317. KIM JY, Park JE, Jo Y, Shim WH, et al
    Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Neuro Oncol. 2018 Aug 11. pii: 5069926. doi: 10.1093.
    PubMed     Abstract available


  318. TEJADA NEYRA MA, Neuberger U, Reinhardt A, Brugnara G, et al
    Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.
    Neuro Oncol. 2018 Aug 9. pii: 5068679. doi: 10.1093.
    PubMed     Abstract available


  319. KOK JL, Teepen JC, van Leeuwen FE, Tissing WJE, et al
    Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age.
    Neuro Oncol. 2018 Aug 7. pii: 5067497. doi: 10.1093.
    PubMed     Abstract available


  320. HUANG RY, Unadkat P, Linda Bi W, George E, et al
    Response Assessment of Meningioma: 1D, 2D and Volumetric Criteria for Treatment Response and Tumor Progression.
    Neuro Oncol. 2018 Aug 2. pii: 5063817. doi: 10.1093.
    PubMed     Abstract available


  321. HARTMANN C
    Inclusion bias of patients with genetically different glioblastoma subgroups in clinical trials.
    Neuro Oncol. 2018 Aug 1. pii: 5063295. doi: 10.1093.
    PubMed    


    July 2018
  322. CHO HJ, Zhao J, Jung SW, Ladewig E, et al
    Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
    Neuro Oncol. 2018 Jul 31. pii: 5061885. doi: 10.1093.
    PubMed     Abstract available


  323. PARK AK, Kim P, Ballester LY, Esquenazi Y, et al
    Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Neuro Oncol. 2018 Jul 25. pii: 5059682. doi: 10.1093.
    PubMed     Abstract available


  324. KATHAGEN-BUHMANN A, Maire CL, Weller J, Schulte A, et al
    The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have antiproliferative effects.
    Neuro Oncol. 2018 Jul 24. pii: 5057755. doi: 10.1093.
    PubMed     Abstract available


  325. SUH CH, Kim HS, Jung SC, Choi CG, et al
    2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data.
    Neuro Oncol. 2018 Jul 18. pii: 5055433. doi: 10.1093.
    PubMed     Abstract available


  326. SPIEGL-KREINECKER S, Lotsch D, Neumayer K, Kastler L, et al
    TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
    Neuro Oncol. 2018 Jul 11. pii: 5052146. doi: 10.1093.
    PubMed     Abstract available


  327. LASSMAN AB, van den Bent MJ, Gan HK, Reardon DA, et al
    Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Neuro Oncol. 2018 Jul 5. pii: 5049251. doi: 10.1093.
    PubMed     Abstract available


  328. THEELER BJ
    De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter.
    Neuro Oncol. 2018;20:1009-1010.
    PubMed    


  329. CIMINO PJ, McFerrin L, Wirsching HG, Arora S, et al
    Copy number profiling across glioblastoma populations has implications for clinical trial design.
    Neuro Oncol. 2018 Jul 2. pii: 5047422. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  330. LEE EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY, et al
    Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
    Neuro Oncol. 2018 Jun 27. pii: 5046042. doi: 10.1093.
    PubMed    


  331. MICHAELSEN SR, Staberg M, Pedersen H, Jensen KE, et al
    VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance.
    Neuro Oncol. 2018 Jun 25. pii: 5043488. doi: 10.1093.
    PubMed     Abstract available


  332. SA JK, Kim SH, Lee JK, Cho HJ, et al
    Identification of Genomic and Molecular Traits that Present Therapeutic Vulnerability to HGF-targeted therapy in Glioblastoma.
    Neuro Oncol. 2018 Jun 23. pii: 5043207. doi: 10.1093.
    PubMed     Abstract available


  333. ANDRONESI OC
    Precision oncology in the era of radiogenomics: the case of D-2HG as an imaging biomarker for mutant IDH gliomas.
    Neuro Oncol. 2018;20:865-867.
    PubMed    


  334. LAL S, Carrera D, Phillips JJ, Weiss WA, et al
    An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
    Neuro Oncol. 2018 Jun 14. pii: 5038008. doi: 10.1093.
    PubMed     Abstract available


  335. BROWN DA, Himes BT, Kerezoudis P, Chilinda-Salter YM, et al
    Insurance Correlates with Improved Access to Care and Outcome Among Glioblastoma Patients.
    Neuro Oncol. 2018 Jun 11. pii: 5035412. doi: 10.1093.
    PubMed     Abstract available


  336. KUNZ M, Albert NL, Unterrainer M, la Fougere C, et al
    Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
    Neuro Oncol. 2018 Jun 9. pii: 5035376. doi: 10.1093.
    PubMed     Abstract available


  337. FALK DELGADO A, De Luca F, van Westen D, Falk Delgado A, et al
    Arterial Spin Labeling MR imaging for differentiation between high and low grade glioma - a meta-analysis.
    Neuro Oncol. 2018 Jun 2. pii: 5032325. doi: 10.1093.
    PubMed     Abstract available


  338. LOMBARDI G, Della Puppa A, Gardiman MP, Rossi S, et al
    Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma.
    Neuro Oncol. 2018 Jun 2. pii: 5032324. doi: 10.1093.
    PubMed    


    May 2018
  339. ZHANG L, He L, Lugano R, Roodakker K, et al
    IDH-mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower Grade Gliomas.
    Neuro Oncol. 2018 May 29. pii: 5018656. doi: 10.1093.
    PubMed     Abstract available


  340. DASGUPTA A, Gupta T, Pungavkar S, Shirsat N, et al
    Nomograms based on Pre-operative Multi-parametric Magnetic Resonance Imaging for Prediction of Molecular Subgrouping in Medulloblastoma: Results from a Radiogenomics Study of 111 Patients.
    Neuro Oncol. 2018 May 29. pii: 5018966. doi: 10.1093.
    PubMed     Abstract available


  341. JOSEPH SK, Samaha H, Bielamowicz K, Ahmed N, et al
    Invited Response to the Comment by Caruso and Heimberger on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma" by Bielamowicz et al.
    Neuro Oncol. 2018 May 19. pii: 4999739. doi: 10.1093.
    PubMed    


  342. EICKHOFF J, Robins HI
    Survival of patients with prior anti-angiogenic therapy.
    Neuro Oncol. 2018;20:860-861.
    PubMed    


  343. BROWN NF, Williams M, Arkenau HT, Fleming RA, et al
    A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
    Neuro Oncol. 2018 May 17. pii: 4998845. doi: 10.1093.
    PubMed     Abstract available


  344. GILLESPIE S, Monje M
    An Active Role for Neurons in Glioma Progression: Making Sense of Scherer's Structures.
    Neuro Oncol. 2018 May 17. pii: 4998849. doi: 10.1093.
    PubMed     Abstract available


  345. GEURTS M, van den Bent MJ
    Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?
    Neuro Oncol. 2018 May 15. pii: 4996074. doi: 10.1093.
    PubMed    


  346. VAN DEN BOSSCHE WBL, Kleijn A, Teunissen CE, Voerman JSA, et al
    Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    Neuro Oncol. 2018 May 15. pii: 4996453. doi: 10.1093.
    PubMed     Abstract available


  347. CLAUS EB, Cornish AJ, Broderick P, Schildkraut JM, et al
    Genome-wide association analysis identifies a meningioma risk locus at 11p15.5.
    Neuro Oncol. 2018 May 12. pii: 4995586. doi: 10.1093.
    PubMed     Abstract available


  348. CLOUGHESY TF, Landolfi J, Vogelbaum MA, Ostertag D, et al
    Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.
    Neuro Oncol. 2018 May 12. pii: 4995454. doi: 10.1093.
    PubMed     Abstract available


  349. PUDELKO L, Edwards S, Balan M, Nyqvist D, et al
    An orthotopic glioblastoma animal model suitable for high-throughput screenings.
    Neuro Oncol. 2018 May 10. pii: 4994699. doi: 10.1093.
    PubMed     Abstract available


  350. ZACHARIAH M, Oliveira-Costa JP, Carter B, Stott SL, et al
    Blood-Based Biomarkers for the Diagnosis and Monitoring of Gliomas.
    Neuro Oncol. 2018 May 9. pii: 4994194. doi: 10.1093.
    PubMed    


  351. GUPTA N, Goumnerova LC, Manley P, Chi SN, et al
    Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma.
    Neuro Oncol. 2018 May 5. pii: 4993208. doi: 10.1093.
    PubMed     Abstract available


  352. KARACHI A, Dastmalchi F, Mitchell D, Rahman M, et al
    Temozolomide for Immunomodulation in the Treatment of Glioblastoma.
    Neuro Oncol. 2018 May 4. pii: 4992672. doi: 10.1093.
    PubMed     Abstract available


  353. PAECH D, Windschuh J, Oberhollenzer J, Dreher C, et al
    Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multi-pool CEST MRI at 7.0 Tesla.
    Neuro Oncol. 2018 May 4. pii: 4992691. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  354. STADLBAUER A, Zimmermann M, Doerfler A, Oberndorfer S, et al
    Intratumoral Heterogeneity of Oxygen Metabolism and Neovascularization Uncovers Two Survival Relevant Subgroups of IDH1 Wild-type Glioblastoma.
    Neuro Oncol. 2018 Apr 28. pii: 4989834. doi: 10.1093.
    PubMed     Abstract available


  355. ELLINGSON BM, Abrey LE, Garcia J, Chinot O, et al
    Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo.
    Neuro Oncol. 2018 Apr 20. pii: 4979515. doi: 10.1093.
    PubMed     Abstract available


  356. HERSH DS, Harder BG, Roos A, Peng S, et al
    The TNF Receptor Family Member Fn14 is Highly Expressed in Recurrent Glioblastoma (GBM) and in GBM Patient-Derived Xenografts With Acquired Temozolomide Resistance.
    Neuro Oncol. 2018 Apr 20. pii: 4979510. doi: 10.1093.
    PubMed     Abstract available


  357. DU Z, Brewster R, Merrill PH, Chmielecki J, et al
    Meningioma transcription factors link cell lineage with systemic metabolic cues.
    Neuro Oncol. 2018 Apr 12. pii: 4969420. doi: 10.1093.
    PubMed     Abstract available


  358. KOGA T, Li B, Figueroa JM, Ren B, et al
    Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Neuro Oncol. 2018 Apr 12. pii: 4969527. doi: 10.1093.
    PubMed     Abstract available


  359. CARUSO H, Heimberger AB
    Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".
    Neuro Oncol. 2018 Apr 10. pii: 4965825. doi: 10.1093.
    PubMed    


  360. HEGI ME, Kleihues P, Wen PY, Suva ML, et al
    Toward methylation-based classification of central nervous system tumors.
    Neuro Oncol. 2018;20:579-581.
    PubMed    


  361. LEVIN VA, Ellingson BM
    Understanding brain penetrance of anticancer drugs.
    Neuro Oncol. 2018;20:589-596.
    PubMed     Abstract available


  362. WILKE C, Grosshans D, Duman J, Brown P, et al
    Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults.
    Neuro Oncol. 2018;20:597-607.
    PubMed     Abstract available


  363. MENDEZ JS, Ostrom QT, Gittleman H, Kruchko C, et al
    The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.
    Neuro Oncol. 2018;20:687-694.
    PubMed     Abstract available


  364. LINNINGER A, Hartung GA, Liu BP, Mirkov S, et al
    Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Neuro Oncol. 2018 Apr 5. pii: 4962158. doi: 10.1093.
    PubMed     Abstract available


  365. ELLINGSON BM, Abrey LE, Nelson SJ, Kaufmann TJ, et al
    Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962189. doi: 10.1093.
    PubMed     Abstract available


  366. ELLINGSON BM, Aftab DT, Schwab GM, Hessel C, et al
    Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Neuro Oncol. 2018 Apr 5. pii: 4962211. doi: 10.1093.
    PubMed     Abstract available


  367. ALEXANDER BM, Cloughesy TF
    Platform trials arrive on time for glioblastoma.
    Neuro Oncol. 2018 Apr 2. pii: 4958219. doi: 10.1093.
    PubMed    


    March 2018
  368. AKBARI H, Bakas S, Pisapia JM, Nasrallah MP, et al
    In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
    Neuro Oncol. 2018 Mar 30. pii: 4956862. doi: 10.1093.
    PubMed     Abstract available


  369. BABAK S, Mason WP
    mTOR inhibition in glioblastoma: requiem for a dream?
    Neuro Oncol. 2018 Mar 28. pii: 4955983. doi: 10.1093.
    PubMed    


  370. NASSIRI F, Aldape K, Zadeh G
    The multiforme of glioblastoma.
    Neuro Oncol. 2018;20:437-438.
    PubMed    


  371. LEVIN VA
    Drug discovery in neuro-oncology: challenges in the path forward.
    Neuro Oncol. 2018;20:435-436.
    PubMed    


  372. JORDAN JT, Sanders AE, Armstrong T, Asher T, et al
    Quality improvement in neurology: Neuro-Oncology Quality Measurement Set.
    Neuro Oncol. 2018;20:531-537.
    PubMed    


  373. HSIEH TH, Liu YR, Chang TY, Liang ML, et al
    Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
    Neuro Oncol. 2018;20:519-530.
    PubMed     Abstract available


  374. BOXERMAN JL, Zhang Z, Safriel Y, Rogg JM, et al
    Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686.
    Neuro Oncol. 2018 Mar 26. pii: 4953723. doi: 10.1093.
    PubMed     Abstract available


  375. BROEN MPG, Smits M, Wijnenga MMJ, Dubbink HJ, et al
    The T2-FLAIR Mismatch Sign as an Imaging Marker for Non-Enhancing IDH-mutant, 1p/19q-intact Lower Grade Glioma: A Validation Study.
    Neuro Oncol. 2018 Mar 26. pii: 4953716. doi: 10.1093.
    PubMed     Abstract available


  376. ANGUS SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, et al
    EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Neuro Oncol. 2018 Mar 21. pii: 4947870. doi: 10.1093.
    PubMed     Abstract available


  377. SAADEH FS, Melamed EF, Rea ND, Krieger MD, et al
    Seizure outcomes of supratentorial brain tumor resection in pediatric patients.
    Neuro Oncol. 2018 Mar 20. pii: 4944459. doi: 10.1093.
    PubMed     Abstract available


  378. PEDROSA R, Mustafa DA, Soffietti R, Kros JM, et al
    Breast cancer brain metastasis: molecular mechanisms and directions for treatment.
    Neuro Oncol. 2018 Mar 16. pii: 4939604. doi: 10.1093.
    PubMed     Abstract available


  379. HE J, Zhao Y, Zhao E, Wang X, et al
    Cancer-testis Specific Gene OIP5: A Downstream Gene of E2F1 that Promotes Tumorigenesis and Metastasis in Glioblastoma by Stabilizing E2F1 Signalling.
    Neuro Oncol. 2018 Mar 14. pii: 4934327. doi: 10.1093.
    PubMed     Abstract available


  380. APPAY R, Tabouret E, Macagno N, Touat M, et al
    IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.
    Neuro Oncol. 2018 Mar 7. pii: 4924365. doi: 10.1093.
    PubMed    


  381. VANDERBEEK AM, Rahman R, Fell G, Ventz S, et al
    The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
    Neuro Oncol. 2018 Mar 6. pii: 4922286. doi: 10.1093.
    PubMed     Abstract available


  382. COY S, Rashid R, Lin JR, Du Z, et al
    Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma.
    Neuro Oncol. 2018 Mar 2. pii: 4917565. doi: 10.1093.
    PubMed     Abstract available


  383. BAGLEY SJ, Desai AS, Linette GP, June CH, et al
    CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges.
    Neuro Oncol. 2018 Mar 2. pii: 4917531. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  384. PARK JW, Wollmann G, Urbiola C, Fogli B, et al
    Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
    Neuro Oncol. 2018 Feb 23. pii: 4904223. doi: 10.1093.
    PubMed     Abstract available


  385. OSTROM QT, Rubin JB, Lathia JD, Berens ME, et al
    Females have the survival advantage in glioblastoma.
    Neuro Oncol. 2018 Feb 21. pii: 4883496. doi: 10.1093.
    PubMed    


  386. PACE A, Walbert T
    Simultaneous care in neuro-oncology.
    Neuro Oncol. 2018;20:302-303.
    PubMed    


  387. KRUCHKO C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS, et al
    The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone.
    Neuro Oncol. 2018;20:295-298.
    PubMed    


  388. BLUMENTHAL DT, Won M, Mehta MP, Gilbert MR, et al
    Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database.
    Neuro Oncol. 2018 Feb 15. pii: 4861801. doi: 10.1093.
    PubMed     Abstract available


  389. BASKARAN S, Mayrhofer M, Kultima HG, Bergstrom T, et al
    Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages.
    Neuro Oncol. 2018 Feb 15. pii: 4860173. doi: 10.1093.
    PubMed     Abstract available


  390. CHOI S, Yu Y, Grimmer MR, Wahl M, et al
    Temozolomide-associated Hypermutation in Gliomas.
    Neuro Oncol. 2018 Feb 14. pii: 4857168. doi: 10.1093.
    PubMed     Abstract available


  391. ZHOU M, Zhou Y, Liao H, Rowland BC, et al
    Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas.
    Neuro Oncol. 2018 Feb 9. pii: 4846845. doi: 10.1093.
    PubMed     Abstract available


  392. ABOUNADER R
    A new practical and versatile mouse model of proneural glioblastoma.
    Neuro Oncol. 2018 Feb 8. pii: 4842815. doi: 10.1093.
    PubMed    


  393. ALDAPE K, Amin SB, Ashley DM, Barnholtz-Sloan JS, et al
    Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2018 Feb 8. pii: 4843984. doi: 10.1093.
    PubMed     Abstract available


  394. LIAO P, Ostrom QT, Stetson L, Barnholtz-Sloan JS, et al
    Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence.
    Neuro Oncol. 2018 Feb 8. pii: 4844022. doi: 10.1093.
    PubMed     Abstract available


  395. BRENNER A, Zuniga R, Sun JD, Floyd J, et al
    Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I surgical study.
    Neuro Oncol. 2018 Feb 5. pii: 4838327. doi: 10.1093.
    PubMed     Abstract available


  396. NHAT TRAN A, Walker K, Harrison DG, Chen W, et al
    Reactive Species Balance via GTP Cyclohydrolase I Regulates Glioblastoma Growth and Tumor Initiating Cell Maintenance.
    Neuro Oncol. 2018 Feb 2. pii: 4835145. doi: 10.1093.
    PubMed     Abstract available


  397. LOUVRIER C, Pasmant E, Briand-Suleau A, Cohen J, et al
    Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Neuro Oncol. 2018 Feb 2. pii: 4835073. doi: 10.1093.
    PubMed     Abstract available


  398. MONCAYO G, Grzmil M, Smirnova T, Zmarz P, et al
    SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
    Neuro Oncol. 2018 Feb 1. pii: 4833547. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  399. ALDAVE G, Gonzalez-Huarriz M, Rubio A, Romero JP, et al
    The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
    Neuro Oncol. 2018 Jan 24. pii: 4823831. doi: 10.1093.
    PubMed     Abstract available


  400. AUDIA A, Bhat KP
    Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas.
    Neuro Oncol. 2018;20:151-152.
    PubMed    


  401. RUBIN JB, Finlay JL
    Pediatric low-grade gliomas: a brave new world.
    Neuro Oncol. 2018;20:149-150.
    PubMed    


  402. STROWD RE, Kim AH, Wen PY
    Meeting Update-Society for Neuro-Oncology 2017 Annual Meeting.
    Neuro Oncol. 2018;20:156-159.
    PubMed    


  403. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:144-145.
    PubMed    


  404. HARRELD JH
    Comment on "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee".
    Neuro Oncol. 2018;20:143-144.
    PubMed    


  405. ALDAPE K
    A change at the helm of Neuro-Oncology.
    Neuro Oncol. 2018;20:1.
    PubMed    


  406. PRUST ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, et al
    Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss.
    Neuro Oncol. 2018 Jan 5. pii: 4791799. doi: 10.1093.
    PubMed    


  407. CHIN AL, Moding EJ, Donaldson SS, Gibbs IC, et al
    Survival Impact of Postoperative Radiotherapy Timing in Pediatric and Adolescent Medulloblastoma.
    Neuro Oncol. 2018 Jan 4. pii: 4788577. doi: 10.1093.
    PubMed     Abstract available


  408. RUDA R, Soffietti R
    Extent of surgery in low-grade gliomas: an old question in a new context.
    Neuro Oncol. 2018 Jan 3. pii: 4788257. doi: 10.1093.
    PubMed    


    December 2017
  409. PARK J, Shim JK, Kang JH, Choi J, et al
    Regulation of bioenergetics through dual inhibition of aldehyde dehydrogenase and mitochondrial complex I suppresses glioblastoma tumorspheres.
    Neuro Oncol. 2017 Dec 23. pii: 4773887. doi: 10.1093.
    PubMed     Abstract available


  410. MAHLOKOZERA T, Vellimana AK, Li T, Mao DD, et al
    Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737220. doi: 10.1093.
    PubMed     Abstract available


  411. CALMON R, Puget S, Varlet P, Dangouloff-Ros V, et al
    Cerebral blood flow changes after radiation therapy identifies pseudo-progression in diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Dec 13. pii: 4737113. doi: 10.1093.
    PubMed     Abstract available


  412. IUS T, Ciani Y, Ruaro ME, Isola M, et al
    A NF-kappaB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.
    Neuro Oncol. 2017 Dec 7. pii: 4708291. doi: 10.1093.
    PubMed     Abstract available


  413. PEYRE M, Gauchotte G, Giry M, Froehlich S, et al
    De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Neuro Oncol. 2017 Dec 5. pii: 4694050. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  414. GUERRINI-ROUSSEAU L, Dufour C, Varlet P, Masliah-Planchon J, et al
    Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis.
    Neuro Oncol. 2017 Nov 24. pii: 4657092. doi: 10.1093.
    PubMed     Abstract available


  415. PFAFF E, Kessler T, Balasubramanian GP, Berberich A, et al
    Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.
    Neuro Oncol. 2017 Nov 18. doi: 10.1093.
    PubMed     Abstract available


  416. DOVER LL, Dulaney CR, Williams CP, Fiveash JB, et al
    Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Abstract available


  417. ABDELBAKI MS, Boue DR, Finlay JL, Kieran MW, et al
    Desmoplastic Nodular Medulloblastoma in Young Children: A Management Dilemma.
    Neuro Oncol. 2017 Nov 15. doi: 10.1093.
    PubMed     Abstract available


  418. NASSIRI F, Zadeh G, Aldape K
    IDH mutation testing in gliomas-where do we draw the line?
    Neuro Oncol. 2017 Nov 11. doi: 10.1093.
    PubMed    


  419. LAKS DR, Oses-Prieto JA, Alvarado AG, Nakashima J, et al
    A Molecular Cascade Modulates MAP1B and Confers Resistance to mTOR Inhibition in Human Glioblastoma.
    Neuro Oncol. 2017 Nov 9. doi: 10.1093.
    PubMed     Abstract available


  420. SCHAFER N, Proescholdt M, Steinbach JP, Weyerbrock A, et al
    Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
    Neuro Oncol. 2017 Nov 7. doi: 10.1093.
    PubMed     Abstract available


  421. GONDI V, Mehta MP
    Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed    


  422. CHINNAIYAN P, Won M, Wen PY, Rojiani AM, et al
    A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.
    Neuro Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Abstract available


  423. CARAGHER SP, Hall RR 3rd, Ahsan R, Ahmed AU, et al
    Monoamines in Glioblastoma: complex biology with therapeutic potential.
    Neuro Oncol. 2017 Nov 4. doi: 10.1093.
    PubMed     Abstract available


  424. WANG J, Yang ZY, Guo YF, Kuang JY, et al
    Targeting different domains of gap junction protein to control malignant glioma.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Abstract available


  425. BANASAVADI-SIDDEGOWDA YK, Welker AM, An M, Yang X, et al
    PRMT5 as a druggable target for glioblastoma therapy.
    Neuro Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Abstract available


  426. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2017 Nov 1. doi: 10.1093.
    PubMed     Abstract available


    October 2017
  427. DEUMELANDT K, Platten M, Ochs K
    Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed    


  428. OMURO A, Vlahovic G, Lim M, Sahebjam S, et al
    Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.
    Neuro Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Abstract available


  429. GAN HK, Reardon DA, Lassman AB, Merrell R, et al
    Safety, Pharmacokinetics and Antitumor Response of Depatuxizumab Mafodotin as Monotherapy or in Combination with Temozolomide in Patients with Glioblastoma.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  430. HAYES J, Yu Y, Jalbert LE, Mazor T, et al
    Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Abstract available


  431. PLATTEN M
    EGFRvIII vaccine in glioblastoma-InACT-IVe or not ReACTive enough?
    Neuro Oncol. 2017;19:1425-1426.
    PubMed    


  432. UNTERRAINER M, Niyazi M, Ruf V, Bartenstein P, et al
    The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
    Neuro Oncol. 2017 Oct 17. doi: 10.1093.
    PubMed    


  433. FORST D, Adams E, Nipp R, Martin A, et al
    Hospice Utilization in Patients with Malignant Gliomas.
    Neuro Oncol. 2017 Oct 16. doi: 10.1093.
    PubMed     Abstract available


  434. ELLINGSON BM, Wen PY, Cloughesy TF
    Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.
    Neuro Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Abstract available


  435. ESKILSSON E, Rosland GV, Solecki G, Wang Q, et al
    EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  436. RUIZ VY, Praska CE, Armstrong G, Kollmeyer TM, et al
    Molecular Subtyping of Tumors from Patients with Familial Glioma.
    Neuro Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Abstract available


  437. CLOUGHESY TF, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
    Neuro Oncol. 2017 Oct 3. doi: 10.1093.
    PubMed     Abstract available


  438. JOHN-PAUL K, Bartels U
    Intracystic interferon-alpha in pediatric craniopharyngioma patients-reply.
    Neuro Oncol. 2017;19:1420-1421.
    PubMed    


  439. PENAS-PRADO M, de Groot J
    CATNON interim results: another triumph of upfront chemotherapy in glioma.
    Neuro Oncol. 2017;19:1287-1288.
    PubMed    


  440. CAVALHEIRO S
    Intracystic interferon-alpha in pediatric craniopharyngioma patients.
    Neuro Oncol. 2017;19:1419.
    PubMed    


  441. LOU E
    Can you hear them now? Tumor microtubes form cellular communication networks that protect gliomas from surgical lesions and chemotherapy treatments.
    Neuro Oncol. 2017;19:1289-1291.
    PubMed    


    September 2017
  442. KICKINGEREDER P, Neuberger U, Bonekamp D, Piechotta PL, et al
    Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma.
    Neuro Oncol. 2017 Sep 28. doi: 10.1093.
    PubMed     Abstract available


  443. MALTA TM, de Souza CF, Sabedot TS, Silva TC, et al
    Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  444. KAUR S, Ramdzan ZM, Guiot MC, Li L, et al
    CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide.
    Neuro Oncol. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  445. SAHM F, Wick A
    ID(H)entifying checkpoint inhibitor candidates among diffuse glioma.
    Neuro Oncol. 2017 Sep 23. doi: 10.1093.
    PubMed    


  446. BIELAMOWICZ K, Fousek K, Byrd TT, Samaha H, et al
    Trivalent CAR T-cells Overcome Interpatient Antigenic Variability in Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Abstract available


  447. HEFFRON TP
    Challenges of developing small molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Abstract available


  448. PRIDHAM KJ, Le L, Guo S, Varghese RT, et al
    PIK3CB/p110beta is a Selective Survival Factor for Glioblastoma.
    Neuro Oncol. 2017 Sep 16. doi: 10.1093.
    PubMed     Abstract available


  449. POETSCH N, Woehrer A, Gesperger J, Furtner J, et al
    Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for survival of newly diagnosed and treatment naive gliomas.
    Neuro Oncol. 2017 Sep 9. doi: 10.1093.
    PubMed     Abstract available


  450. HARDY KK, Willard VW, Gioia A, Sharkey C, et al
    Attention-mediated neurocognitive profiles in survivors of pediatric brain tumors: Comparison to children with neurodevelopmental ADHD.
    Neuro Oncol. 2017 Sep 8. doi: 10.1093.
    PubMed     Abstract available


  451. SARKARIA JN, Hu LS, Parney IF, Pafundi DH, et al
    Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Abstract available


  452. WIJNENGA MMJ, French PJ, Dubbink HJ, Dinjens WNM, et al
    The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis.
    Neuro Oncol. 2017 Sep 7. doi: 10.1093.
    PubMed     Abstract available


  453. SHIBAO S, Minami N, Koike N, Fukui N, et al
    Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.
    Neuro Oncol. 2017 Sep 2. doi: 10.1093.
    PubMed     Abstract available


  454. BALASUBRAMANIYAN V, Bhat KP
    Targeting MIR155HG in glioma: a novel approach.
    Neuro Oncol. 2017;19:1152-1153.
    PubMed    


  455. COONEY T, Lane A, Bartels U, Bouffet E, et al
    Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study.
    Neuro Oncol. 2017;19:1279-1280.
    PubMed    


  456. SCHNEIDER M, Reitter EM, Kastner MT, Thannesberger J, et al
    Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment.
    Neuro Oncol. 2017;19:1280-1282.
    PubMed    


  457. GOERIG NL, Frey B, Uberla K, Gaipl U, et al
    A clinician's plea to test glioma patients for CMV.
    Neuro Oncol. 2017;19:1282-1283.
    PubMed    


  458. NOWOSIELSKI M, Ellingson BM, Chinot OL, Garcia J, et al
    Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio.
    Neuro Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Abstract available


    August 2017
  459. ANDERSEN ZJ, Pedersen M, Weinmayr G, Stafoggia M, et al
    Long-term Exposure to Ambient Air Pollution and Incidence of Brain Tumor: the European Study of Cohorts for Air Pollution Effects (ESCAPE).
    Neuro Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Abstract available


  460. SZULZEWSKY F, Schwendinger N, Guneykaya D, Cimino PJ, et al
    Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment.
    Neuro Oncol. 2017 Aug 26. doi: 10.1093.
    PubMed     Abstract available


  461. TAUNK NK, Oh JH, Shukla-Dave A, Beal K, et al
    Early Post-treatment Assessment of MRI Perfusion Biomarkers Can Predict Long-term Response of Lung Cancer Brain Metastases to Stereotactic Radiosurgery.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Abstract available


  462. KESSLER T, Sahm F, Sadik A, Stichel D, et al
    Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Neuro Oncol. 2017 Aug 24. doi: 10.1093.
    PubMed     Abstract available


  463. KHAGI S, Miller CR
    Putting "multiforme" back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.
    Neuro Oncol. 2017 Aug 23. doi: 10.1093.
    PubMed    


  464. GALANIS E, Anderson SK, Miller CR, Sarkaria JN, et al
    Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.
    Neuro Oncol. 2017 Aug 22. doi: 10.1093.
    PubMed     Abstract available


  465. DAGMAR D, Proescholdt M, Reinert C, Pietsch T, et al
    Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
    Neuro Oncol. 2017 Aug 21. doi: 10.1093.
    PubMed     Abstract available


  466. WEN PY, Drappatz J, de Groot J, Prados MD, et al
    Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Abstract available


  467. LANG FM, Hossain A, Gumin J, Momin EN, et al
    Mesenchymal Stem Cells as Natural Bio-Factories for Exosomes Carrying miR-124a in the Treatment of Gliomas.
    Neuro Oncol. 2017 Aug 14. doi: 10.1093.
    PubMed     Abstract available


  468. KARREMANN M, Gielen GH, Hoffmann M, Wiese M, et al
    Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Neuro Oncol. 2017 Aug 4. doi: 10.1093.
    PubMed     Abstract available


  469. JONES DTW, Kieran MW, Bouffet E, Alexandrescu S, et al
    Pediatric Low-Grade Gliomas: Next Biologically Driven Steps.
    Neuro Oncol. 2017 Aug 2. doi: 10.1093.
    PubMed     Abstract available


  470. GROSSMAN SA, Kleinberg L
    A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
    Neuro Oncol. 2017;19:1019-1020.
    PubMed    


    July 2017
  471. MANDEL JJ, Yust-Katz S, Patel AJ, Cachia D, et al
    Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.
    Neuro Oncol. 2017 Jul 31. doi: 10.1093.
    PubMed     Abstract available


  472. GARNIER D, Meehan B, Kislinger T, Daniel P, et al
    Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Neuro Oncol. 2017 Jul 28. doi: 10.1093.
    PubMed     Abstract available


  473. PHILIP J, Collins A, Brand C, Sundararajan V, et al
    A Proposed Framework of Supportive and Palliative Care for people with High Grade Glioma.
    Neuro Oncol. 2017 Jul 27. doi: 10.1093.
    PubMed     Abstract available


  474. BHERE D, Tamura K, Wakimoto H, Choi SH, et al
    microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
    Neuro Oncol. 2017 Jul 25. doi: 10.1093.
    PubMed     Abstract available


  475. SPERANZA MC, Passaro C, Ricklefs F, Kasai K, et al
    Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma.
    Neuro Oncol. 2017 Jul 24. doi: 10.1093.
    PubMed     Abstract available


  476. LEVESLEY J, Steele L, Bruning-Richardson A, Davison A, et al
    Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.
    Neuro Oncol. 2017 Jul 20. doi: 10.1093.
    PubMed     Abstract available


  477. SCHREIBER JE, Palmer SL, Conklin HM, Mabbott DJ, et al
    Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study.
    Neuro Oncol. 2017 Jul 19. doi: 10.1093.
    PubMed     Abstract available


  478. AOKI K, Nakamura H, Suzuki H, Matsuo K, et al
    Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Abstract available


  479. WICK A, Kessler T, Elia AEH, Winkler F, et al
    Glioblastoma in the elderly: solid conclusions built on shifting sand?
    Neuro Oncol. 2017 Jul 18. doi: 10.1093.
    PubMed     Abstract available


  480. SHAN X, Fan X, Liu X, Zhao Z, et al
    Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis.
    Neuro Oncol. 2017 Jul 17. doi: 10.1093.
    PubMed     Abstract available


  481. COULDWELL WT, Cannon-Albright LA
    A description of familial clustering of meningiomas in the Utah population.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


  482. WU S, Wang S, Gao F, Li L, et al
    Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


  483. JAHAN N, Talat H, Curry WT
    Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


  484. RAHME GJ, Luikart BW, Cheng C, Israel MA, et al
    A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


  485. TIROSH I, Suva ML
    Dissecting human gliomas by single-cell RNA sequencing.
    Neuro Oncol. 2017 Jul 7. doi: 10.1093.
    PubMed     Abstract available


  486. OKADA H, Thorne SH
    Is the immune response a friend or foe for viral therapy of glioma?
    Neuro Oncol. 2017;19:882-883.
    PubMed    


  487. ZHANG Z, Chan AK, Ding X, Li Y, et al
    Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Neuro Oncol. 2017;19:1008-1010.
    PubMed    


    June 2017
  488. OLMEZ I, Love S, Xiao A, Manigat L, et al
    Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
    Neuro Oncol. 2017 Jun 29. doi: 10.1093.
    PubMed     Abstract available


  489. QIAN Y, Maruyama S, Kim H, Pollom EL, et al
    Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Abstract available


  490. DEWITT JC, Jordan JT, Frosch MP, Samore WR, et al
    Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.
    Neuro Oncol. 2017 Jun 28. doi: 10.1093.
    PubMed     Abstract available


  491. JIN L, Ge H, Long Y, Yang C, et al
    CD70, a novel target of CAR-T-cell therapy for gliomas.
    Neuro Oncol. 2017 Jun 23. doi: 10.1093.
    PubMed     Abstract available


  492. DIAMOND EL, Prigerson HG, Correa DC, Reiner A, et al
    Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma.
    Neuro Oncol. 2017 Jun 22. doi: 10.1093.
    PubMed     Abstract available


  493. GUTMANN DH
    Caddyshack therapeutics: overcoming glioblastoma adaptation.
    Neuro Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed    


  494. GALLDIKS N, Albert NL, Sommerauer M, Grosu AL, et al
    PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Abstract available


  495. WU J, Frady LN, Bash RE, Cohen SM, et al
    MerTK as a therapeutic target in glioblastoma.
    Neuro Oncol. 2017 Jun 12. doi: 10.1093.
    PubMed     Abstract available


  496. KIERAN MW, Chisholm J, Casanova M, Brandes AA, et al
    Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
    Neuro Oncol. 2017 Jun 9. doi: 10.1093.
    PubMed     Abstract available


  497. MORROW AM, Morgan RM, Villano JL
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials-impact of psychogenic non-epileptic seizures.
    Neuro Oncol. 2017 Jun 6. doi: 10.1093.
    PubMed    


  498. WANG X, Holgado BL, Ramaswamy V, Mack S, et al
    "miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"
    Neuro Oncol. 2017 Jun 2. doi: 10.1093.
    PubMed     Abstract available


  499. ZHOU X, Xie S, Wu S, Qi Y, et al
    Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Abstract available


  500. SEPULVEDA-SANCHEZ JM, Vaz MA, Balana C, Gil-Gil M, et al
    Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Neuro Oncol. 2017 Jun 1. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  501. ABUDUMIJITI A, Chan AK, Shi Z, Li Y, et al
    Adult IDH Wild-type Lower-grade Gliomas Should Be Further Stratified.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Abstract available


  502. ZHU C, Kros JM, Cheng C, Mustafa D, et al
    The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.
    Neuro Oncol. 2017 May 27. doi: 10.1093.
    PubMed     Abstract available


  503. NABORS LB
    When less is better: care of the elderly with glioblastoma.
    Neuro Oncol. 2017 May 26. doi: 10.1093.
    PubMed    


  504. GLASS JO, Ogg RJ, Hyun JW, Harreld JH, et al
    Disrupted development and integrity of frontal white matter in patients treated for pediatric medulloblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Abstract available


  505. KESARWANI P, Kant S, Prabhu A, Chinnaiyan P, et al
    The interplay between metabolic remodeling and immune regulation in glioblastoma.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Abstract available


  506. PRABHU A, Kesarwani P, Kant S, Graham SF, et al
    Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis.
    Neuro Oncol. 2017 May 25. doi: 10.1093.
    PubMed     Abstract available


  507. KIERAN MW
    Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed    


  508. JACKSON S, ElAli A, Virgintino D, Gilbert MR, et al
    Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.
    Neuro Oncol. 2017 May 24. doi: 10.1093.
    PubMed     Abstract available


  509. KARIMI S, Vyas MV, Gonen L, Tabasinejad R, et al
    Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Abstract available


  510. BERGHOFF AS, Kiesel B, Widhalm G, Wilhelm D, et al
    Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Abstract available


  511. NOWOSIELSKI M, Galldiks N, Iglseder S, Kickingereder P, et al
    Diagnostic Challenges in Meningioma.
    Neuro Oncol. 2017 May 20. doi: 10.1093.
    PubMed     Abstract available


  512. COLMAN H
    Toward more informative biomarker-based clinical trials in glioblastoma.
    Neuro Oncol. 2017 May 17. doi: 10.1093.
    PubMed    


  513. GROSSMANN P, Narayan V, Chang K, Rahman R, et al
    Quantitative Imaging Biomarkers for Risk Stratification of Patients with Recurrent Glioblastoma Treated with Bevacizumab.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Abstract available


  514. KILDAY JP, Caldarelli M, Massimi L, Chen RH, et al
    Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.
    Neuro Oncol. 2017 May 11. doi: 10.1093.
    PubMed     Abstract available


  515. SHANKAR GM, Santagata S
    BAP1 mutations in high-grade meningioma: implications for patient care.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Abstract available


  516. SCHMIDT C, Schubert NA, Brabetz S, Mack N, et al
    Pre-clinical drug screen reveals topotecan, actinomycin D and volasertib as potential new therapeutic candidates for ETMR brain tumor patients.
    Neuro Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Abstract available


  517. YESILOZ U, Kirches E, Hartmann C, Scholz J, et al
    Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Neuro Oncol. 2017 May 6. doi: 10.1093.
    PubMed     Abstract available


  518. SILGINER M, Nagy S, Happold C, Schneider H, et al
    Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.
    Neuro Oncol. 2017 May 5. doi: 10.1093.
    PubMed     Abstract available


  519. NARLOCH JL, Farber SH, Sammons S, McSherry F, et al
    Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.
    Neuro Oncol. 2017 May 3. doi: 10.1093.
    PubMed     Abstract available


  520. MASON W
    NANO, a practical scale for neurologic assessments in patients with brain tumors?
    Neuro Oncol. 2017;19:603-604.
    PubMed    


  521. GITTLEMAN H, Lim D, Kattan MW, Chakravarti A, et al
    An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Neuro Oncol. 2017;19:669-677.
    PubMed     Abstract available


  522. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2017;19:719-725.
    PubMed     Abstract available


  523. TERRIER LM, Bauchet L, Rigau V, Amelot A, et al
    Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database.
    Neuro Oncol. 2017;19:678-688.
    PubMed     Abstract available


  524. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2017;19:660-668.
    PubMed     Abstract available


  525. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2017;19:636-647.
    PubMed     Abstract available


  526. NAYAK L, DeAngelis LM, Brandes AA, Peereboom DM, et al
    The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
    Neuro Oncol. 2017;19:625-635.
    PubMed     Abstract available


  527. ZHU C, Mustafa D, Zheng PP, van der Weiden M, et al
    Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.
    Neuro Oncol. 2017;19:648-659.
    PubMed     Abstract available


  528. KLINE CN, Joseph NM, Grenert JP, van Ziffle J, et al
    Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
    Neuro Oncol. 2017;19:699-709.
    PubMed     Abstract available


    April 2017
  529. FIGUEROA JM, Skog J, Akers J, Li H, et al
    Detection of wtEGFR Amplification and EGFRvIII Mutation in CSF-Derived Extracellular Vesicles of Glioblastoma Patients.
    Neuro Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Abstract available


  530. WARREN KE, Vezina G, Poussaint TY, Warmuth-Metz M, et al
    Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee.
    Neuro Oncol. 2017 Apr 25. doi: 10.1093.
    PubMed     Abstract available


  531. CAGNEY DN, Martin AM, Catalano PJ, Redig AJ, et al
    Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study.
    Neuro Oncol. 2017 Apr 24. doi: 10.1093.
    PubMed     Abstract available


  532. BROKINKEL B, Hess K, Mawrin C
    Brain invasion in Meningiomas - Clinical considerations and impact of neuropathological evaluation: A systematic Review.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Abstract available


  533. WEIL S, Osswald M, Solecki G, Grosch J, et al
    Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
    Neuro Oncol. 2017 Apr 17. doi: 10.1093.
    PubMed     Abstract available


  534. VITUCCI M, Irvin DM, McNeill RS, Schmid RS, et al
    Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
    Neuro Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Abstract available


  535. MITCHELL LA, Lopez Espinoza F, Mendoza D, Kato Y, et al
    Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
    Neuro Oncol. 2017 Apr 6. doi: 10.1093.
    PubMed     Abstract available


  536. THOMPSON EM, Keir ST, Venkatraman T, Lascola C, et al
    The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Abstract available


  537. LIN AL, DeAngelis LM
    Reappraising the 2016 WHO classification for diffuse glioma.
    Neuro Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed    


  538. WEN PY, Jiang T, Schiff D
    How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies.
    Neuro Oncol. 2017;19:459-460.
    PubMed    


  539. GROSSMAN SA, Schreck KC, Ballman K, Alexander B, et al
    Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2017;19:469-474.
    PubMed    


  540. GROSSHANS DR, Mohan R, Gondi V, Shih HA, et al
    The role of image-guided intensity modulated proton therapy in glioma.
    Neuro Oncol. 2017;19.
    PubMed     Abstract available


  541. SAHGAL A, Ruschin M, Ma L, Verbakel W, et al
    Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.
    Neuro Oncol. 2017;19.
    PubMed     Abstract available


  542. GRANBERG KJ, Annala M, Lehtinen B, Kesseli J, et al
    Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Neuro Oncol. 2017 Apr 1. doi: 10.1093.
    PubMed     Abstract available


  543. CAO Y, Tseng CL, Balter JM, Teng F, et al
    MR-guided radiation therapy: transformative technology and its role in the central nervous system.
    Neuro Oncol. 2017;19.
    PubMed     Abstract available


  544. KIRKPATRICK JP, Soltys SG, Lo SS, Beal K, et al
    The radiosurgery fractionation quandary: single fraction or hypofractionation?
    Neuro Oncol. 2017;19.
    PubMed     Abstract available


  545. CHAMBERLAIN M, Junck L, Brandsma D, Soffietti R, et al
    Leptomeningeal metastases: a RANO proposal for response criteria.
    Neuro Oncol. 2017;19:484-492.
    PubMed     Abstract available


  546. MYNAREK M, Pizer B, Dufour C, van Vuurden D, et al
    Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data.
    Neuro Oncol. 2017;19:576-585.
    PubMed     Abstract available


  547. BATCHELOR TT, Gerstner ER, Ye X, Desideri S, et al
    Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-beta tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Neuro Oncol. 2017;19:567-575.
    PubMed     Abstract available


  548. HARDCASTLE J, Mills L, Malo CS, Jin F, et al
    Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Neuro Oncol. 2017;19:493-502.
    PubMed     Abstract available


    March 2017
  549. AHMED KA, Berglund AE, Welsh EA, Naghavi AO, et al
    The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity.
    Neuro Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed    


  550. HUANG R
    Response assessment in high-grade glioma: tumor volume as endpoint.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed    


  551. FOULADI M, Pfister SM
    MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed    


  552. MCNEILL RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, et al
    Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    Neuro Oncol. 2017 Mar 30. doi: 10.1093.
    PubMed     Abstract available


  553. COHEN KJ, Jabado N, Grill J
    Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  554. BLUMENTHAL DT, Gorlia T, Gilbert MR, Kim MM, et al
    Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  555. WU X, Wang Y, Yu T, Nie E, et al
    Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  556. WANG C, Kaprealian TB, Suh JH, Kubicky CD, et al
    Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  557. HODGES TR, Ott M, Xiu J, Gatalica Z, et al
    Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Neuro Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  558. HOLDHOFF M, Ye X, Supko JG, Nabors LB, et al
    Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro Oncol. 2017 Mar 22. doi: 10.1093.
    PubMed     Abstract available


  559. LAWLER SE
    Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment.
    Neuro Oncol. 2017 Mar 16. doi: 10.1093.
    PubMed    


  560. JEON MS, Dhillon HM, Agar MR
    Sleep disturbance of adults with a brain tumor and their family caregivers: a systematic review.
    Neuro Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Abstract available


  561. HU X, Martinez-Ledesma E, Zheng S, Kim H, et al
    Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Abstract available


  562. MEI X, Chen YS, Chen FR, Xi SY, et al
    Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.
    Neuro Oncol. 2017 Mar 8. doi: 10.1093.
    PubMed     Abstract available


  563. ALVAREZ-BRECKENRIDGE C, Brastianos PK
    SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.
    Neuro Oncol. 2017;19:305-306.
    PubMed    


  564. JENKINSON MD, Santarius T, Zadeh G, Aldape KD, et al
    Atypical meningioma-is it time to standardize surgical sampling techniques?
    Neuro Oncol. 2017;19:453-454.
    PubMed    


  565. YANG W, Garzon-Muvdi T, Braileanu M, Porras JL, et al
    Primary intramedullary spinal cord lymphoma: a population-based study.
    Neuro Oncol. 2017;19:414-421.
    PubMed     Abstract available


  566. TABOURET E, Houillier C, Martin-Duverneuil N, Blonski M, et al
    Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
    Neuro Oncol. 2017;19:422-429.
    PubMed     Abstract available


  567. ALDAPE K, Nejad R, Louis DN, Zadeh G, et al
    Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.
    Neuro Oncol. 2017;19:336-344.
    PubMed     Abstract available


  568. BENTLEY RT, Ahmed AU, Yanke AB, Cohen-Gadol AA, et al
    Dogs are man's best friend: in sickness and in health.
    Neuro Oncol. 2017;19:312-322.
    PubMed     Abstract available


    February 2017
  569. ARIF T, Kerlin Y, Nakdimon I, Benharroch D, et al
    VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Abstract available


  570. BANERJEE A, Jakacki RI, Onar-Thomas A, Wu S, et al
    A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed     Abstract available


  571. COTE DJ, Downer MK, Zoltick ES, Smith TR, et al
    ABO blood group and risk of glioma.
    Neuro Oncol. 2017 Feb 28. doi: 10.1093.
    PubMed    


  572. ANDERSON JL, Muraleedharan R, Oatman N, Klotter A, et al
    The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Neuro Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Abstract available


  573. HUANG YT, Zhang Y, Wu Z, Michaud DS, et al
    Genotype-based gene signature of glioma risk.
    Neuro Oncol. 2017 Feb 22. doi: 10.1093.
    PubMed     Abstract available


  574. VAN DEN BENT MJ, Weller M, Wen PY, Kros JM, et al
    A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.
    Neuro Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Abstract available


  575. TANGUTURI SK, Trippa L, Ramkissoon SH, Pelton K, et al
    Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.
    Neuro Oncol. 2017 Feb 20. doi: 10.1093.
    PubMed     Abstract available


  576. FREYSCHLAG CF, Kerschbaumer J, Thome C
    Comment on: Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
    Neuro Oncol. 2017 Feb 18. doi: 10.1093.
    PubMed    


  577. GAHRMANN R, van den Bent M, van der Holt B, Vernhout RM, et al
    Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  578. HEINZEL A, Muller D, Yekta-Michael SS, Ceccon G, et al
    O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  579. D'ALESSANDRIS QG, Biffoni M, Martini M, Runci D, et al
    The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  580. ABOU-EL-ARDAT K, Seifert M, Becker K, Eisenreich S, et al
    Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  581. MEYRONET D, Esteban-Mader M, Bonnet C, Joly MO, et al
    Characteristics of H3 K27M-mutant gliomas in adults.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  582. TEGLASI V, Reiniger L, Fabian K, Pipek O, et al
    Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.
    Neuro Oncol. 2017 Feb 13. doi: 10.1093.
    PubMed    


  583. RUDA R, Soffietti R
    Controversies in management of low-grade gliomas in light of new data from clinical trials.
    Neuro Oncol. 2017;19:143-144.
    PubMed    


  584. RODDY E, Mueller S
    Response to "Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of paediatric brain tumors".
    Neuro Oncol. 2017;19:299-300.
    PubMed    


  585. PASSOS J, Nzwalo H, Marques J, Azevedo A, et al
    Cognitive function, cerebral microbleeds, radiotherapy, and bevacizumab in survivors of pediatric brain tumors.
    Neuro Oncol. 2017;19:298-299.
    PubMed    


  586. SOFFIETTI R, Abacioglu U, Baumert B, Combs SE, et al
    Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).
    Neuro Oncol. 2017;19:162-174.
    PubMed     Abstract available


  587. CHANG S, Zhang P, Cairncross JG, Gilbert MR, et al
    Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
    Neuro Oncol. 2017;19:252-258.
    PubMed     Abstract available


  588. MIRANDA-FILHO A, Pineros M, Soerjomataram I, Deltour I, et al
    Cancers of the brain and CNS: global patterns and trends in incidence.
    Neuro Oncol. 2017;19:270-280.
    PubMed     Abstract available


    January 2017
  589. ZHOU H, Vallieres M, Bai HX, Su C, et al
    MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Neuro Oncol. 2017 Jan 24. doi: 10.1093.
    PubMed     Abstract available


  590. ANTONIOS JP, Soto H, Everson RG, Moughon D, et al
    Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Neuro Oncol. 2017 Jan 23. pii: now287. doi: 10.1093.
    PubMed     Abstract available


  591. RAMKISSOON SH, Bandopadhayay P, Hwang J, Ramkissoon LA, et al
    Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
    Neuro Oncol. 2017 Jan 19. pii: now294. doi: 10.1093.
    PubMed     Abstract available


  592. COLWELL N, Larion M, Giles AJ, Seldomridge AN, et al
    Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.
    Neuro Oncol. 2017 Jan 19. doi: 10.1093.
    PubMed     Abstract available


  593. BERGHOFF AS, Wolpert F, Holland-Letz T, Koller R, et al
    Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.
    Neuro Oncol. 2017 Jan 17. pii: now290. doi: 10.1093.
    PubMed     Abstract available


  594. BOETTO J, Bielle F, Sanson M, Peyre M, et al
    SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Neuro Oncol. 2017 Jan 12. pii: now276. doi: 10.1093.
    PubMed     Abstract available


  595. AYUSO JM, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, et al
    Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events.
    Neuro Oncol. 2017 Jan 6. pii: now230. doi: 10.1093.
    PubMed     Abstract available


  596. TENG J, Carla da Hora C, Kantar RS, Nakano I, et al
    Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Neuro Oncol. 2017 Jan 6. pii: now253. doi: 10.1093.
    PubMed     Abstract available


  597. CHAMBERLAIN MC, Baik CS, Gadi VK, Bhatia S, et al
    Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
    Neuro Oncol. 2017;19:i1-i24.
    PubMed     Abstract available


  598. BOWMAN RL, Wang Q, Carro A, Verhaak RG, et al
    GlioVis data portal for visualization and analysis of brain tumor expression datasets.
    Neuro Oncol. 2017;19:139-141.
    PubMed    


  599. GUPTA NK, Nolan A, Omuro A, Reid EG, et al
    Long-term survival in AIDS-related primary central nervous system lymphoma.
    Neuro Oncol. 2017;19:99-108.
    PubMed     Abstract available


  600. RALEIGH DR, Solomon DA, Lloyd SA, Lazar A, et al
    Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.
    Neuro Oncol. 2017;19:78-88.
    PubMed     Abstract available


    December 2016
  601. WIEDMANN MK, Brunborg C, Di Ieva A, Lindemann K, et al
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study.
    Neuro Oncol. 2016 Dec 31. pii: now272. doi: 10.1093.
    PubMed     Abstract available


  602. CICONE F, Galldiks N, Minniti G, Filss CP, et al
    Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury.
    Neuro Oncol. 2016 Dec 31. pii: now283. doi: 10.1093.
    PubMed    


  603. YOUNG RJ, Yang TJ, Hatzoglou V, Ulaner G, et al
    "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
    Neuro Oncol. 2016 Dec 31. pii: now286. doi: 10.1093.
    PubMed    


  604. MARISETTY AL, Singh SK, Nguyen TN, Coarfa C, et al
    REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.
    Neuro Oncol. 2016 Dec 31. pii: now232. doi: 10.1093.
    PubMed     Abstract available


  605. ROTH P, Valavanis A, Weller M
    Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Neuro Oncol. 2016 Dec 29. pii: now265. doi: 10.1093.
    PubMed    


  606. KING AA, Seidel K, Di C, Leisenring WM, et al
    Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study.
    Neuro Oncol. 2016 Dec 29. pii: now242. doi: 10.1093.
    PubMed     Abstract available


  607. REARDON DA, Lassman AB, van den Bent M, Kumthekar P, et al
    Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
    Neuro Oncol. 2016 Dec 29. pii: now257. doi: 10.1093.
    PubMed     Abstract available


  608. TSCHERPEL C, Dunkl V, Ceccon G, Stoffels G, et al
    The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
    Neuro Oncol. 2016 Dec 29. pii: now243. doi: 10.1093.
    PubMed     Abstract available


  609. ZHANG AS, Ostrom QT, Kruchko C, Rogers L, et al
    Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010.
    Neuro Oncol. 2016 Dec 29. pii: now252. doi: 10.1093.
    PubMed     Abstract available


  610. ZAMANIPOOR NAJAFABADI AH, Peeters MC, Dirven L, Lobatto DJ, et al
    Impaired health-related quality of life in meningioma patients-a systematic review.
    Neuro Oncol. 2016 Dec 29. pii: now250. doi: 10.1093.
    PubMed     Abstract available


  611. TOONEN JA, Ma Y, Gutmann DH
    Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
    Neuro Oncol. 2016 Dec 29. pii: now267. doi: 10.1093.
    PubMed     Abstract available


  612. LIU TT, Achrol AS, Mitchell LA, Rodriguez SA, et al
    Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment.
    Neuro Oncol. 2016 Dec 22. pii: now270. doi: 10.1093.
    PubMed     Abstract available


  613. SHAHAR T, Rozovski U, Hess KR, Hossain A, et al
    Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  614. LEE J, Hoxha E, Song HR
    A novel NFIA-NFkappaB feed-forward loop contributes to glioblastoma cell survival.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  615. PENG S, Dhurv H, Armstrong B, Salhia B, et al
    Integrated genomic analysis of survival outliers in glioblastoma.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  616. HAN YP, Enomoto A, Shiraki Y, Wang SQ, et al
    Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  617. KLEIN M
    Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma.
    Neuro Oncol. 2016;18:1595-1596.
    PubMed    


  618. SCHIFF D
    Molecular profiling optimizes the treatment of low-grade glioma.
    Neuro Oncol. 2016;18:1593-1594.
    PubMed    


    November 2016
  619. LASORELLA A, Sanson M, Iavarone A
    FGFR-TACC gene fusions in human glioma.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  620. SHANKAR GM, Abedalthagafi M, Vaubel RA, Merrill PH, et al
    Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
    Neuro Oncol. 2016 Nov 9. doi: 10.1093.
    PubMed    


  621. ARMSTRONG FD
    Evidence of cerebral microbleeds and neurocognitive impairment following cranial radiation therapy for pediatric brain tumors: a new opportunity for improved care.
    Neuro Oncol. 2016;18:1470-1471.
    PubMed    


    October 2016
  622. YAGHI NK, Wei J, Hashimoto Y, Kong LY, et al
    Immune modulatory nanoparticle therapeutics for intracerebral glioma.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  623. MENEI P, Clavreul A, Lemee JM
    Response To "Glioma Resection and Tumor Recurrence: Back To Semmelweis".
    Neuro Oncol. 2016.
    PubMed    


  624. RATEL D, van der Sanden B, Wion D
    Glioma resection and tumor recurrence: back to Semmelweis.
    Neuro Oncol. 2016.
    PubMed    


    September 2016
  625. PACKER RJ, Pfister S, Bouffet E, Avery R, et al
    Pediatric low-grade gliomas: implications of the biologic era.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  626. VAN WEST SE, de Bruin HG, van de Langerijt B, Swaak-Kragten AT, et al
    Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  627. AVILA EK, Chamberlain M, Schiff D, Reijneveld JC, et al
    Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  628. WAGNER S, Lanfermann H, Eichner G, Gufler H, et al
    Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI.
    Neuro Oncol. 2016.
    PubMed     Abstract available


  629. PINHEIRO KV, Alves C, Buendia M, Gil MS, et al
    Targeting tyrosine receptor kinase B in gliomas.
    Neuro Oncol. 2016.
    PubMed    


  630. GUNDEMIR S, Monteagudo A, Akbar A, Keillor JW, et al
    The complex role of transglutaminase 2 in glioblastoma proliferation.
    Neuro Oncol. 2016 Sep 2. doi: 10.1093.
    PubMed    


    February 2016
  631. BAUMGARTEN P, Blank AE, Franz K, Hattingen E, et al
    Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Neuro Oncol. 2016;18:173-83.
    PubMed     Abstract available


  632. RUDA R, Bosa C, Magistrello M, Franchino F, et al
    Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
    Neuro Oncol. 2016;18:261-8.
    PubMed     Abstract available


    January 2016
  633. ROUSE C, Gittleman H, Ostrom QT, Kruchko C, et al
    Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.
    Neuro Oncol. 2016;18:70-7.
    PubMed     Abstract available


  634. LEE JK, Chang N, Yoon Y, Yang H, et al
    USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance.
    Neuro Oncol. 2016;18:37-47.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: